Document:

<PAGE>

          PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED ON A REQUEST FOR
                                CONFIDENTIAL TREATMENT

                                                                   Exhibit 10.22

                              COLLABORATION AGREEMENT

      THIS COLLABORATION AGREEMENT (this "Agreement") is entered into as of June
27, 2000, by and among DELTAGEN, INC. ("Deltagen"), a Delaware corporation with
a place of business at 1003 Hamilton Avenue, Menlo Park, CA 94025, U.S.A., and
GLAXO GROUP LIMITED ("GGL") and GLAXO RESEARCH AND DEVELOPMENT LIMITED ("GWRD"),
each incorporated in England with a place of business at Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 ONN, United Kingdom.

      NOW, THEREFORE, in consideration of the promises and the mutual covenants
and conditions set forth in this Agreement, the parties agree as follows:

                                     ARTICLE 1
                                    DEFINITIONS

1.1   "Affiliate" shall mean, with respect to a party to this Agreement, any
entity directly or indirectly controlling or controlled by or in common control
with such party, where "control" is defined as the ownership of at least *** of
the equity or beneficial interests of such entity, or the right to vote for or
appoint a majority of the board of directors or other governing body of such
entity.

1.2   "Access Term" shall mean, with respect to each Phenotype Set delivered to
Glaxo Wellcome hereunder, the period commencing on the date on which Glaxo
Wellcome *** and ending on the *** for such Phenotype Set.

1.3   "Competent Jurisdiction" shall mean any of the following jurisdictions:
***.

1.4   "Confidential Information" shall mean, the content of this Agreement, the
Deltagen Proprietary Information, the DeltaBase Functionality and, with respect
to a party, all data and/or information of any kind whatsoever (including
without limitation, data, databases, compilations, formulae, schemata, models,
patent disclosures, procedures, processes, projections, protocols, results of
experimentation and testing, specifications, strategies and techniques), and all
tangible and intangible embodiments thereof of any kind whatsoever (including
without limitation, apparatus, compositions, documents, drawings, machinery,
patent applications, records, laboratory and research notebooks, memoranda and
reports), which are disclosed by such party to the other party and is marked,
identified as or otherwise acknowledged to be confidential at the time of
disclosure to the other party.  Notwithstanding the foregoing, the obligations
of the parties with respect to Confidential Information set forth in Article 7
below shall not apply to data and/or information which the other party can
establish by written documentation (a) to have been publicly known prior to
disclosure of such data and/or information by the disclosing party to the other
party, (b) to have become publicly known, without fault on the part of the other
party, subsequent to disclosure of such data and/or information by the
disclosing party to the other party, (c) to have been received by the other
party at any time from a source, other than the

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

<PAGE>

disclosing party, rightfully having possession of and a right to disclose such
data and/or information, (d) to have been otherwise known by the other party
prior to disclosure of such data and/or information by the disclosing party to
the other party, or (e) to have been independently developed by the employees or
agents of the other party without access to or the use of such data and/or
information disclosed by the disclosing party to the other party.

1.5   "Data Set" shall mean the collective group of Phenotype Sets designated by
Deltagen for inclusion in DeltaBase and delivered to Glaxo Wellcome hereunder in
a given *** of DeltaBase Information under Section 3.2.1 below.

1.6   "DeltaBase" shall mean Deltagen's database consisting of DeltaBase
Information and DeltaBase Functionality.

1.7   "DeltaBase Access Plan" shall mean the plan mutually agreed to by the
parties hereto, substantially in the form of Exhibit A, which establishes
mechanisms for Glaxo Wellcome to document access to the DeltaBase and ensure
compliance with the parameters of such access.

1.8   "DeltaBase Functionality" shall mean the DeltaBase software and
documentation provided to Glaxo Wellcome hereunder; provided, however, that the
DeltaBase Functionality shall exclude all Third Party hardware and software,
including the Third Party hardware and software listed on Exhibit B.

1.9   "DeltaBase Information" shall mean the *** and related data and/or
information, generated or developed by or on behalf of Deltagen from or relating
to *** and entered into one or more databases *** or as to which ***, to be
provided under a subscription to DeltaBase on a nonexclusive basis to DeltaBase
subscribers generally (including Glaxo Wellcome).  Notwithstanding the
foregoing, DeltaBase Information shall not include data or information generated
or developed by or on behalf of Deltagen that is for its or its Affiliates' use,
for use on an exclusive basis by one or more specific Third Parties, and not
intended by Deltagen for inclusion in DeltaBase.

1.10  "Deltagen Patent Rights" shall mean patents and/or patent applications
owned by *** to Deltagen, as of the Effective Date or during the Access Term,
which comprise (a) with respect to ***, any claims covering making, having made,
using, selling, offering for sale, importing or otherwise commercializing *** or
(b) with respect to a ***, any claim covering (i) ***, or uses thereof; or (ii)
***, or uses thereof; and including any divisions, continuations, re-issues,
re-examinations, extensions or other governmental actions which extend any of
the subject matter of such patent applications or patents; provided that
Deltagen Patent Rights shall exclude the Excluded Patent Rights.

1.11  "Deltagen Proprietary Information" shall mean DeltaBase Information that
is confidential and/or proprietary to Deltagen and/or its Affiliates or
licensor(s); provided however, that Deltagen Proprietary Information shall
exclude any data or information that, at the time of first disclosure by
Deltagen, was (a) publicly known prior to such disclosure or (b) already in the
possession of Glaxo Wellcome or (c) generated or developed by or for Glaxo
Wellcome independently and entirely without access to or any reference to or use
of any Deltagen Information, unless such independently generated or developed
data or information or its

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -2-
<PAGE>

generation, development or use, absent the rights and licenses granted by this
Agreement, would infringe any of the Deltagen Patent Rights.

1.12  "Derivative Work" shall mean any and all modifications, improvements,
enhancements, translations, abridgments and the like to ***, and includes,
without limitation, (a) for copyrightable or copyrighted material, any
modification, translation including translation into other computer languages,
port, abridgment, condensation, expansion, correction, addition, extension,
adaptation, extraction, or other form in which such material may be recast,
transformed, or adapted which if prepared without a license to do so would
result in copyright infringement; (b) for patentable or patented material, any
improvement thereon; and (c) for material which is protected by trade secret,
any new material derived from such existing trade secret material, including new
material which may be protected by copyright, patent and/or trade secret laws.

1.13  "Derived" or "derived" shall mean obtained, developed, created, tested,
identified, discovered, synthesized, designed, or resulting from, based upon or
otherwise generated (whether directly or indirectly, or in whole or in part).

1.14  "Designated Gene" shall mean a Target Gene ***.

1.15  "Designated Mutated Gene" shall mean the Mutated Gene that corresponds to
a Designated Gene.

1.16  "Diagnostic Product" shall mean any product, other than a database,
that is (1) for use in (a) the *** in humans (including, without limitation,
the ***), (b) the selection of *** in humans, and (c) the *** in humans and (2)
is derived from the use of, or makes any use of any (i)*** (ii) ***, (iii)
*** (iv) Deltagen Proprietary Information or (v) Deltagen Patent Rights.

1.17  "Effective Date" shall mean the date on which Glaxo Wellcome receives the
first Data Set from Deltagen, which shall be no later than September 1, 2000.

1.18  "ES Cell Line" shall mean, with respect to a Designated Gene, the
embryonic stem cell line used to produce a line of Knockout Mice containing
within their genome the corresponding Designated Mutated Gene.

1.19  "Excluded Patent Rights" shall mean (a) the patents and/or patent
applications owned by, *** Deltagen claiming (i) *** (ii) any product,
formulation or composition, or the use of any product, formulation or
composition, *** (iii) *** or (iv) *** (except that claims described by
sub-clauses (a)(iii) and (a)(iv) above shall not be considered Excluded Patent
Rights and shall be included within the definition of Deltagen Patent Rights,
***; and (b) any divisions, continuations, continuations-in-part, reissues,
reexaminations, extensions or other governmental actions which extend any of the
subject matter of the patent applications or patents in (a) above.

1.20  "Extended Access Term" shall mean, with respect to each Phenotype Set
delivered to Glaxo Wellcome hereunder, the period commencing on the expiration
of the Initial Access Term for such Phenotype Set, and ending on *** of such
Initial Access Term for such Phenotype Set under Section 3.1.5 below.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -3-
<PAGE>

1.21  "FDA" shall mean the US Food & Drug Administration.

1.22  "***" with respect to Knockout Mice is defined in Section 5.1.1.

1.23  "Glaxo Wellcome" shall mean, collectively, GGL, GWRD and their respective
Affiliates.

1.24  "Health Registration" shall mean, with respect to a Product, approval for
marketing and sale of that Product by the requisite governmental or regulatory
authority ***.

1.25  "Initial Access Term" shall mean, with respect to each Phenotype Set
delivered to Glaxo Wellcome hereunder, the period commencing on the date on
which Glaxo Wellcome first receives such Phenotype Set, and ending on the later
of (a) *** the date on which Glaxo Wellcome first ***, or (b) the *** of the
Effective Date.

1.26  "Installation Sites" shall mean the site(s) where the DeltaBase is
installed pursuant to this Agreement and shall in the first instance be limited
to:

           *** (the "First Installation Site")

and subsequently to any other research facilities of Glaxo Wellcome nominated by
Glaxo Wellcome and agreed to in writing by Deltagen.

1.27  "Knockout Mice" or "Knockout Mouse" shall mean, with respect to a ***,
mice or a mouse containing ***.

1.28  "Lead Optimization" shall mean the process of ***.

1.29  "Major Market Country" shall mean any of the following countries: ***.

1.30  "Material Transfer Agreement" shall mean a material transfer agreement in
the form set out in Exhibit F or a modified version thereof with all changes
thereto approved by Deltagen in writing.

1.31  "Mutated Gene" shall mean a *** chosen or targeted by Deltagen and used by
Deltagen in the generation of Knockout Mice, ***.

1.32  "Person" shall mean an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company,
joint venture, pool, syndicate, sole proprietorship, unincorporated
organization, governmental authority or any other form of entity not
specifically listed herein.

1.33  "Phenotype Set" shall mean, with respect to a distinct *** and entered
into one or more databases comprising DeltaBase. During the applicable Access
Term, ***.

1.34  "Pre-clinical Candidate Selection" shall mean the point at which ***.

1.35  "Proof Of Concept" shall mean the *** by or for Glaxo Wellcome.

1.36  "Product(s)" shall mean, collectively, ***.  Notwithstanding anything to
the contrary in

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -4-
<PAGE>

this Agreement, ***.

1.37  "Research Partner" shall mean a Person (whether it is in the public or
private sector) that (a) is a university or other academic non-profit entity at
which research is sponsored by Glaxo Wellcome *** Glaxo Wellcome *** of Products
for the sole benefit of Glaxo Wellcome and (b) receives any (i) *** (ii) ***
(iii) ***or (iv) *** under this Agreement; provided, however, no Research
Partner shall be entitled to receive *** unless and until such Research Partner
executes a Material Transfer Agreement and is subject to the obligations of
confidentiality and restrictions on use contained in this Agreement. Upon
reasonable request, Glaxo Wellcome will provide Deltagen with a written list of
all past and current Research Partners receiving such information pursuant to
this Agreement.

1.38  "Target Gene" shall mean a gene or sequence that is described, referenced
or otherwise included in the DeltaBase Information by Deltagen.

1.39  "Therapeutic Product" shall mean any product developed or generated by or
on behalf of Glaxo Wellcome which is (a) comprised of or includes *** active
ingredients and (b) *** (c) derived from the use of, or makes any use of any (i)
*** (ii) ***(iii) *** (iv) DeltaBase Information; or (v) Deltagen Patent Rights.

1.40  "Third Party" shall mean any Person other than Deltagen, Glaxo Wellcome
and their respective Affiliates and/or Research Partners.

1.41  "Valid Claim" shall mean any claim of any particular patent that (a) is
part of the Deltagen Patent Rights; and (b) is issued or granted by any
Competent Jurisdiction; and (c) has not been finally declared unpatentable or
invalid at the completion of post-grant opposition proceedings including any
appeal therefrom; and (d) is unexpired and has not been held unenforceable,
unpatentable or invalid by a court or other governmental body having legal
competency to hear the matter and proper jurisdiction and venue in a decision
that is unappealable, or unappealed within the time allowed for appeal; and (e)
has not been rendered unenforceable through disclaimer or otherwise or been lost
through an interference proceeding.

1.42  "Valid Reach-Through Claim" shall mean a Valid Claim ***.

                                     ARTICLE 2
                 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS

2.1   Mutual Representations and Warranties. Each party hereby represents and
warrants to the other party as follows:

      2.1.1     Corporate Existence.  Such party is a corporation duly
      organized, validly existing and in good standing under the laws of the
      jurisdiction in which it is incorporated.

      2.1.2     Authorization and Enforcement of Obligations.  Such party (a)
      has the requisite power and authority and the legal right to enter into
      this Agreement and to perform its obligations hereunder, and (b) has taken
      all necessary action on its part to authorize the execution and delivery
      of this Agreement and the performance of its obligations hereunder. This
      Agreement has been duly executed and delivered on behalf of such party,
      and constitutes a legal, valid,

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -5-
<PAGE>

      binding obligation, enforceable against such party in accordance with its
      terms.

      2.1.3     Consents.  All necessary consents, approvals and authorizations
      of all governmental authorities and other Persons required to be obtained
      by such party in connection with its execution of this Agreement have been
      obtained.

      2.1.4     No Conflict.  The execution and delivery of this Agreement and
      the performance of such party's obligations hereunder (a) do not conflict
      with or violate any requirement of applicable laws or regulations and (b)
      do not conflict with, or constitute a default under, any contractual
      obligation of such party.

2.2   Deltagen Representation, Warranty, and Covenant.

      2.2.1     Deltagen hereby represents and warrants to Glaxo Wellcome that:

      2.2.1.1   As of the Effective Date, Deltagen is the owner of the Deltagen
           Patent Rights and, ***, has the right to grant the licenses
           thereunder contemplated hereby.

      2.2.1.2   When operated with the recommended Third Party hardware and
           software listed on Exhibit B, the DeltaBase Functionality shall ***.

      2.2.1.3   When operated with the recommended Third Party hardware and
           software listed on Exhibit B, the DeltaBase Functionality will not
           produce errors in processing date and/or time data in connection with
           the year 2000 change, will successfully and correctly transition and,
           with respect to the correct system date, will remain operational and
           properly functioning into and beyond the year 2000, and will
           accurately and correctly process any and all date and/or time data
           from, into and between the twentieth and twenty-first centuries, when
           the DeltaBase Functionality is used with accurate date and/or time
           data in accordance with its documentation, provided that all other
           products used with the DeltaBase Functionality properly exchange date
           and/or time data with the DeltaBase Functionality.

      2.2.1.4   The DeltaBase Information and the Phenotype Sets *** and shall
           *** to generate and develop the data and information contained
           therein.

      2.2.1.5   ***, the DeltaBase Functionality shall not include any so-called
           "computer virus," "worm," or "Trojan horse" or other similar
           malicious computer code.

2.3   In the event of the breach of any representation or warranty by Deltagen
under Section 2.2, Glaxo Wellcome shall provide prompt written notice thereof to
Deltagen describing in reasonably specific detail the nature of the alleged
breach.  With respect to *** (a) in the case where *** or (b) in all other
cases, ***.

2.4   Deltagen shall notify Glaxo Wellcome of *** against or owed ***, or any
***, known to Deltagen, relating to the applicable Deltagen Patent Rights which
Deltagen believes will *** Glaxo Wellcome hereunder.

2.5   For purposes of this Agreement, *** and *** (or phrases to similar effect)
shall mean, in

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -6-
<PAGE>

each case, the knowledge of employees of Deltagen *** with respect to such
subject matter as any reasonably diligent company would perform in the normal
course of its own business operations.

2.6   DISCLAIMER OF WARRANTIES.

      2.6.1     DELTAGEN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR
      IMPLIED, WITH RESPECT TO THE *** OR OTHER RESULTS OF THE ***.

      2.6.2     EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 2,
      DELTAGEN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH
      RESPECT TO ***, THE ***, THE DELTABASE, THE KNOCK-OUT MICE, THE ***, OR
      DELTAGEN PATENT RIGHTS, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF
      MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT OF
      THE PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER
      PERSON.

2.7   Third Party Licenses. Without limiting the generality of the foregoing in
Section 2.6, Glaxo Wellcome hereby acknowledges that Glaxo Wellcome will be
required to obtain (sub)licenses to use *** software and *** in order to use the
DeltaBase Functionality in accordance with this Agreement.

2.8   Governmental Consents and Approvals.  Each party shall be responsible,
at its own expense, for complying with all applicable laws and obtaining all
applicable governmental and regulatory approvals, consents, permits and
licenses to perform its duties and responsibilities under this Agreement. In
particular:-(a) Deltagen shall perform its obligations in conformance with
(i) the Content Criteria, (ii) generally accepted industry standards for
non-clinical research and laboratory animal care and welfare as reasonably
implemented by Deltagen in its facilities and operations, and (iii) if and to
the extent applicable, all other local, state and federal laws, rules,
regulations, and ordinances including, but not limited to, the federal ***
including, but not limited to, *** and the regulations of the *** and (b)
Glaxo Wellcome shall be  responsible for complying with such laws and
obtaining all such governmental and regulatory approvals, consents, permits
and licenses in connection with the ***, as well as in connection with access
to and the receipt, storage, and use of such materials by Glaxo Wellcome in
accordance with this Agreement.  The parties will consult and cooperate each
other with respect to their respective compliance with this Section 2.8.

                                     ARTICLE 3
                                  DELTABASE ACCESS

3.1   Access to the DeltaBase.

      3.1.1     Access.  Subject to the terms and conditions of this Agreement,
      Deltagen shall provide Glaxo Wellcome with access in accordance with
      Exhibit A to the DeltaBase at the Installation Sites during the applicable
      Access Term for each Phenotype Set delivered to Glaxo Wellcome hereunder.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -7-
<PAGE>

      3.1.2     Installation, Maintenance and Support.  Deltagen shall install
      the DeltaBase at the First Installation Site on a mutually acceptable
      date, and thereafter shall during the Access Term *** Glaxo Wellcome.
      Deltagen shall install, and during the Access Term maintain and support,
      the DeltaBase at additional Installation Sites at Deltagen's then current
      rates for installation, maintenance and support, ***.  Deltagen shall
      perform such installation, maintenance and support in accordance with the
      Installation Maintenance and Support Plan attached as Exhibit C.  Deltagen
      and its duly authorized representatives shall have the sole right and
      responsibility for such installation, maintenance and support of the
      DeltaBase and shall install, maintain and support DeltaBase using
      commercially reasonable standards of care ***.  Glaxo Wellcome shall be
      solely responsible at its sole cost for, and shall, obtain the recommended
      Third Party hardware and software listed on Exhibit B.  Glaxo Wellcome
      shall appoint one (1) Glaxo Wellcome employee resident at each
      Installation Site who shall be both (a) the primary person to contact
      Deltagen and (b) the primary contact for Deltagen, for all communications
      regarding the installation, maintenance and support of the DeltaBase at
      such Installation Site.  Glaxo Wellcome shall notify Deltagen in writing
      promptly upon such appointment and thereafter upon any changes in such
      appointments.

      3.1.3     Installation Site.  Except as expressly provided herein, Glaxo
      Wellcome's  use of the DeltaBase shall be limited to the Installation
      Sites. DeltaBase shall be installed on the hard disk of a single
      designated file server at the Installation Sites, but may not be copied
      for individual clients of such server.  Glaxo Wellcome shall be entitled
      to designate *** of DeltaBase (i) for back-up and retrieval purposes only
      and (ii) a test server to enable integration of DeltaBase into Glaxo
      Wellcomes own computer system.  In no event shall Glaxo Wellcome install
      or use the DeltaBase in a manner which would allow unauthorized access.

      3.1.4     Training.  Deltagen shall provide Glaxo Wellcome with ***
      training by *** Deltagen employees regarding the use of the DeltaBase.
      Deltagen additionally shall provide Glaxo Wellcome with *** of training at
      ***, regarding the use of the DeltaBase.  The number of employees to
      receive such training ***.  ***. Deltagen shall provide Glaxo Wellcome
      with such additional training services in such manner, at such rates as
      shall be mutually agreed between the parties, ***.

      3.1.5     Extended Access Term.  Glaxo Wellcome will provide Deltagen with
      written notice of its election under the following subsections of this
      Section 3.1.5, not later than *** prior to the expiration of the then
      Access Term. Failure to provide such notice shall be deemed an election
      not to extend the Access Term. Following receipt of such notice, Deltagen
      will invoice Glaxo Wellcome as appropriate.

           3.1.5.1   With respect to each Phenotype Set delivered to Glaxo
                Wellcome hereunder, Glaxo Wellcome shall have the right to
                extend its period of access to such Phenotype Set for additional
                *** periods commencing on the expiry of the Initial Access Term
                or relevant Extended Access Term as the case may be, by
                notifying Deltagen of its desire to do so as described above
                and paying to Deltagen an amount equal to *** for each ***
                period with respect to such Phenotype Set by the *** in which
                Glaxo Wellcome receives the invoice.

           3.1.5.2   With respect to all Phenotype Sets in a Data Set delivered
                to Glaxo Wellcome in a

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -8-
<PAGE>

           single quarterly installment, Glaxo Wellcome shall have the right to
           extend its access to all Phenotype Sets in such Data Set for
           additional one *** periods, commencing on the expiry of the Initial
           Access Term or relevant Extended Access Term as the case may be, by
           notifying Deltagen of its desire to do so as described above. Glaxo
           Wellcome shall pay to Deltagen an amount equal to *** for each Data
           Set *** in each Data Set for each *** period with respect to all
           Phenotype Sets in such Data Set. Payments due hereunder shall be paid
           by the *** in which Glaxo Wellcome receives the invoice.

      3.1.5.3   With respect to all Phenotype Sets delivered to Glaxo Wellcome
           during the Initial Access Term, Glaxo Wellcome shall have the right
           to extend its access to all such Phenotype Sets for additional ***
           periods, commencing on the expiry of the Initial Access Term or
           relevant Extended Access Term as the case may be,  by notifying
           Deltagen of its desire to do so as described above and paying to
           Deltagen an amount equal to *** for each *** period with respect to
           all Phenotype Sets delivered to Glaxo Wellcome during the Initial
           Access Term by the *** in which Glaxo Wellcome receives the invoice.

3.2   DeltaBase Information.

      3.2.1     Delivery of Phenotype Sets.  During each of the *** of the
      Access Term, Deltagen shall deliver to Glaxo Wellcome *** Data Sets as
      part of the DeltaBase Information.  The Data Sets delivered to Glaxo
      Wellcome on a *** in each year shall include up to a total of ***
      Phenotype Sets per year delivered at the rate of *** Phenotype Sets per
      ***.  If available (and subject to section 3.1.5.2) and if Glaxo Wellcome
      so elects and Deltagen agrees, Glaxo Wellcome may receive Data Sets with
      *** per Data Set ***. If available and if Glaxo Wellcome so elects and
      Deltagen agrees, Glaxo Wellcome may receive Phenotype Sets that are
      designated by Deltagen for inclusion in DeltaBase and delivery to
      DeltaBase subscribers under a DeltaBase subscription, *** per year, by
      paying to Deltagen *** per *** by the *** in which Glaxo Wellcome receives
      the invoice.

      3.2.2     Quality Assurance.  Glaxo Wellcome shall have a period of ***
      after the receipt of each Data Set by Glaxo Wellcome hereunder to ***
      described in Exhibit D as varied with the consent of both parties (the
      "Content Criteria").  In the event that any Data Set *** the Content
      Criteria, Glaxo Wellcome shall provide written notice to Deltagen *** in
      reasonable detail. If Deltagen does not agree that ***, then the matter
      will be addressed by the *** and, if necessary, according to the ***.
      With respect to each ***, Deltagen shall, within *** after its receipt of
      such notice, (a) in the case where *** is the result of or relates to ***,
      ***, mutually agree with Glaxo Wellcome upon a *** or (b) in all other
      cases, ***. If Glaxo Wellcome does not provide written notice of *** with
      respect to such Data Set pursuant to this Section 3.2.2 within such ***
      period, such Data Set shall be *** with the Content Criteria.

      3.2.3     Supplemental DeltaBase Information. During the Access Term for
      each Phenotype Set, Deltagen shall additionally provide to Glaxo Wellcome
      *** with respect to *** to Glaxo Wellcome hereunder that are *** and
      provided under a subscription to DeltaBase on a nonexclusive basis ***
      (including Glaxo Wellcome ). Deltagen, at its sole discretion, also may
      from time to time release to its DeltaBase subscribers (including Glaxo
      Wellcome) as

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -9-
<PAGE>

      part of the general DeltaBase subscription, ***. Deltagen shall send all
      DeltaBase Information to Glaxo Wellcome on a reasonably suitable medium
      (being either Magneto Optical Disk, Tape or CD ROM) under such means
      agreed to by the parties. Notwithstanding the foregoing, such updates and
      supplements shall not include information or data generated or developed
      by or on behalf of Deltagen that is for its or its Affiliates' use, for
      use on an exclusive basis by one or more specific Third Parties, and not
      intended by Deltagen for inclusion in DeltaBase.

3.3   DeltaBase Access Plan.  Glaxo Wellcome shall comply with the DeltaBase
Access Plan at all times during the Access Term.

3.4   Ownership and Use of DeltaBase.

      3.4.1     Ownership.  Notwithstanding anything to the contrary herein, as
      between Deltagen and Glaxo Wellcome, Deltagen shall retain all right,
      title and interest in and to the DeltaBase, including without limitation,
      the DeltaBase Information and all worldwide intellectual property rights
      therein and thereto.

      3.4.2     Permitted Use

      3.4.2.1   Subject to the terms and conditions of this Agreement (including
           without limitation prompt payment of all fees due hereunder), Glaxo
           Wellcome may:- (a) *** use (i) the DeltaBase Information solely to
           conduct internal research and (ii) the DeltaBase Functionality solely
           to search and access the DeltaBase Information, in each case for the
           sole benefit of Glaxo Wellcome, ***.

      3.4.2.2   Glaxo Wellcome shall not disclose, broker, license or otherwise
           grant rights in, sell, assign, or transfer the DeltaBase or any
           portion thereof or any interest therein to any Third Party.  Glaxo
           Wellcome shall not authorize or permit any unauthorized access,
           copying, alteration or installation of the DeltaBase or any portion
           thereof.

      3.4.2.3   Glaxo Wellcome shall not, in part or in whole, reverse engineer,
           decompile, reproduce, publicly display, adapt, modify, prepare
           Derivative Works based upon, or distribute copies (in whatever form,
           whether tangible or intangible, by any means whatsoever whether now
           known or hereafter invented) of the DeltaBase for any purpose except
           to make the *** pursuant to section 3.1.3 *** . Glaxo Wellcome also
           shall have the right to ***.  Any such *** shall be subject to the
           same terms and conditions that apply to DeltaBase under this
           Agreement. Deltagen shall have no obligation to support any such ***.
           Notwithstanding anything to the contrary in this Agreement, the right
           of Glaxo Wellcome *** under this Section 3.4.2.3 shall not diminish
           or otherwise impair Deltagen's right, title and interest in
           DeltaBase.  ***, subject to Deltagen's ownership of and prior rights
           in the DeltaBase Information included or incorporated therein or on
           which such *** is based. In no event, however, shall this Section
           3.4.2.3 be interpreted to allow ***, or any compilation of databases
           that include any DeltaBase Proprietary Information (modified or
           unmodified) for sale, licensing or other commercialization.

      3.4.3     Records on use of DeltaBase. Glaxo Wellcome shall maintain
      records *** of Glaxo Wellcome's access to and use of the ***.  Glaxo
      Wellcome shall maintain such records during the Access Term and for a
      period of *** thereafter. Such records shall be in sufficient detail
      and in a

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -10-
<PAGE>

      format to enable Deltagen to monitor compliance with the terms and
      conditions of this Agreement, including without limitation, the DeltaBase
      Access Plan.  Upon Deltagen's reasonable request ***, Glaxo Wellcome shall
      permit a Deltagen designee (at Deltagen's cost) to have access during
      ordinary business hours to such records as may be reasonably necessary to
      verify compliance with the terms of this Agreement regarding use of the
      DeltaBase for any year not more than *** prior to the date of such
      request. Glaxo Wellcome shall be given not less than *** prior advance
      notice of any request for access.  Such designee shall be bound by
      obligations of confidentiality no less than those contained in this
      Agreement and shall disclose to Deltagen only whether Glaxo Wellcome is in
      compliance with the applicable terms and conditions of this Agreement. If
      such audit reveals that Glaxo Wellcome is in material non-compliance with
      this Agreement, then Glaxo Wellcome shall pay or reimburse the costs of
      and fees for such audit.

      3.4.4     Unauthorized Disclosure or Use.  Glaxo Wellcome shall notify
      Deltagen immediately in the event of any actual or suspected unauthorized
      disclosure or use, loss, or theft of the DeltaBase or any part thereof,
      and shall take all steps reasonably requested by Deltagen to investigate
      and terminate any of the foregoing. Notwithstanding this obligation,
      subject to the terms and conditions of this Agreement, Deltagen confirms
      that during the Access Term, Glaxo Wellcome shall have the right to use
      the DeltaBase solely for Glaxo Wellcome's internal use by authorized
      personnel of Glaxo Wellcome at the Installation Site in secure work
      facilities in accordance with the terms and conditions of this Agreement
      and the DeltaBase Access Plan set out in Exhibit A. Glaxo Wellcome shall
      have no access to or right to use the DeltaBase except at the Installation
      Site under the terms and conditions of this Agreement.

      3.4.5     Record and Reports. Glaxo Wellcome shall keep complete and
      accurate records of its activities conducted under this Agreement and the
      results thereof sufficient to permit Deltagen to confirm the accuracy of
      Glaxo Wellcome's payment obligations under this Agreement. In addition to
      the reports provided pursuant to other Sections of this Agreement for
      billing purposes, within *** during the Access Term and after the end of
      the Access Term, Glaxo Wellcome shall prepare and provide Deltagen with an
      annual written report of the activities conducted under this Agreement
      pursuant to Exhibit E and each year Glaxo Wellcome shall prepare and
      provide to the Escrow Agent the reports set forth in Exhibit E.

3.5   Subscription Fee.  In consideration for the right to access DeltaBase
hereunder, Glaxo Wellcome shall pay to Deltagen the following nonrefundable and
noncreditable amounts on the following dates:

         3.5.1  With respect to the first Data Set delivered to Glaxo Wellcome
      hereunder, *** for ***, which shall be paid as follows: (a) *** which
      Glaxo Wellcome receives the invoice or such Data Set, whichever is later,
      and (b) *** within *** days following receipt by Glaxo Wellcome of the
      Data Set or invoice, whichever is later, provided that payment under
      clause (b) of this Section 3.5.1 shall be subject to Section 3.5.3.

      3.5.2     With respect to each subsequent Data Set delivered to Glaxo
      Wellcome hereunder, *** for *** which shall be paid as follows: (a) *** in
      which Glaxo Wellcome receives the invoice or such Data Set, whichever is
      later, and (b) *** within *** following receipt by Glaxo Wellcome of the
      Data Set or invoice, whichever is later, provided that payment under

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -11-
<PAGE>

      clause (b) of this Section 3.5.2 shall be subject to Section 3.5.3.

      3.5.3     If Glaxo Wellcome gives notice within the requisite *** day
      period under Section 3.2.2 that each Data Set,  as delivered, ***, then
      Glaxo Wellcome *** as the case may be, *** with the Data Set in question
      but *** for each ***    or the *** (b) with respect to ***, whichever is
      lesser.  Amounts, if any, *** will be paid promptly upon ***. Glaxo
      Wellcome's *** certain payments under this Section 3.5.3 shall not affect
      its obligation to make full and timely *** of all other amounts due under
      this Agreement. Any disputes under this section shall be dealt with in
      accordance with Article 12.

                                     ARTICLE 4
                                RIGHTS AND LICENSES

4.1   Rights and Licenses Granted. Subject to the terms and conditions of this
Agreement (including, without limitation, Section 11.5 and the prompt payment of
all fees due under this Article 4), Deltagen hereby grants to Glaxo Wellcome (a)
the right to access and use the DeltaBase and use the Deltagen Proprietary
Information, subject to the terms of this Agreement and for the purposes
contemplated hereby, and (b) a non-exclusive world-wide license under Deltagen
Patent Rights to ***.

4.2   License Fees. Glaxo Wellcome shall pay the following license fees to
Deltagen:-

      4.2.1     *** promptly upon *** with respect to each *** developed or
      generated by or for Glaxo Wellcome.

      4.2.2     *** promptly upon *** with respect to each *** derived from the
      use of a *** where; (a) *** of the ***, , through any ***, the *** or the
      product of *** and; (b) the *** and; (c) the *** describes or covers a ***
      the ***; and (d) the ***.

      4.2.3     (a) *** promptly upon *** with respect to each *** derived from
      the use of a *** and (b) *** promptly upon the obtaining of the *** with
      respect to any *** derived from the use of *** where; (i) a *** of the ***
      is *** through any ***, *** *** the product of the ***; (ii) *** and;
      (iii) the *** describes or covers ***; and (iv) the ***.

      4.2.4     *** promptly upon the *** with respect to a ***.

      4.2.5     (a) *** promptly upon the obtaining of the *** with respect to
      each ***.

4.3   Clarification of Payment Obligations.  It is understood between Glaxo
Wellcome and Deltagen that:

      4.3.1     If a particular *** specific to *** is (a) the subject of ***
      and/or (b) is the subject of *** and Glaxo Wellcome decides to proceed
      instead with one or more other directly related *** specific to the same
      ***, then Glaxo Wellcome shall, with respect to each such ***.

      4.3.2     The timing of the obtaining of *** by Deltagen is not related to
      or coupled with the timing of any of the payment events set forth in
      Section 4.2.  For example, a given Product not previously subject thereto
      may become subject to Section 4.2.3(b) and/or Section 4.2.5

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -12-
<PAGE>

      due to the ***.  In such circumstances, Glaxo Wellcome promptly shall pay
      to Deltagen the highest applicable license fees due under whichever of
      Sections 4.2.2 through 4.2.5 then apply with respect to that Product, ***,
      it being the intent that Deltagen always be paid the maximum license fees
      due under Section 4.2 but that in such cases *** under Sections 4.2.2
      through 4.2.5 shall be payable.

      4.3.3     For the purposes of this Agreement, *** will be differentiated
      from one another, based on whether or not they are, or would be, covered
      by a *** (or the relevant competent authority); provided, however, that a
      given product, formulation or composition grouping will be considered a
      *** even if *** are or would be required *** (or the relevant competent
      authority), if *** are solely due to and/or (b) ***. For the avoidance of
      doubt, if a given ***, or if two or more products, formulations or
      compositions ***, then, subject to the proviso to the preceding sentence,
      each will be considered a separate *** for purposes of this Agreement.

      4.3.4     Payments made pursuant to Section 4.2 are non-creditable, ***,
      and are non-refundable.  Without limiting the generality of the preceding
      sentence, no credit or refund of amounts paid or payable pursuant to
      Sections 4.2.2 through 4.2.5 based on the existence of a ***
      ***. However, the parties agree *** *** for payment under Sections 4.2.2
      through 4.2.5 ***.

4.4   Due Date.  Glaxo Wellcome shall make the payments referred to in Section
4.2 by the *** in which Glaxo Wellcome receives the invoice from Deltagen. Glaxo
Wellcome will report in writing to Deltagen each *** and each *** promptly, and
in any event within thirty (30) days thereafter, so that Deltagen can issue the
corresponding invoice hereunder and receive payment without delay.

4.5   Acknowledgment.  The parties expressly agree that, provided that Glaxo
Wellcome has paid in full all amounts due and otherwise is not in default
hereunder, and subject to the applicable provisions of Article 9, nothing
contained in this Agreement shall restrict in any way whatsoever Glaxo
Wellcome's use and exploitation, either during the Access Term or after the
expiry of the Access Term, of *** in accordance with this Agreement.

4.6   ***  by Glaxo Wellcome or its Research Partners and that contain in their
genome *** of a Knockout Mouse shall be subject to all of the restrictions and
provisions of this Agreement applicable to Knockout Mice ***.

                                     ARTICLE 5
                             USE OF *** KNOCKOUT MICE

5.1   Transfer to Glaxo Wellcome.

      5.1.1     With respect to each ***, if during the applicable Access Term
      Glaxo Wellcome provides written notice to Deltagen of its desire to use
      Knockout Mice containing *** Gene, Deltagen shall transfer to Glaxo
      Wellcome *** of the *** of such Knockout Mouse *** after receiving such
      notice from Glaxo Wellcome. In general, Deltagen intends to *** for each
      line of Knockout Mice and ***. However, if Deltagen in its ordinary course
      of business *** of a line of a Knockout Mouse, then Deltagen shall notify
      Glaxo Wellcome of this fact and, at Glaxo Wellcomes option, either; (a)
      provide Glaxo Wellcome *** Glaxo Wellcome (at Glaxo

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -13-
<PAGE>

      Wellcome's cost) to ***, or Knockout Mice ***, solely for use by Glaxo
      Wellcome on the terms and conditions of this Agreement or (b) *** of
      Knockout Mice or *** (as jointly determined by the parties) for such
      Designated Mutated Gene at costs mutually agreed upon by the parties which
      shall be *** as the costs set out in this Section 5. The use of Knockout
      Mice or *** maintained or obtained by Glaxo Wellcome pursuant to the
      preceding sentence shall be subject to all the terms and conditions of
      this Agreement.

      5.1.2     Glaxo Wellcome may request *** in its notice pursuant to Section
      5.1.1; provided, however, Glaxo Wellcome acknowledges that Deltagen
      maintains *** only and that the availability to Glaxo Wellcome ***.  In
      the event of a request by Glaxo Wellcome for ***, Section 5.1.1 shall not
      apply and the parties instead will negotiate, reasonably and in good
      faith, the quantity, time schedule and amount to be paid for the delivery
      of such Knockout Mice.  Once such terms are mutually agreed, Deltagen will
      send a confirming written notice to Glaxo Wellcome. Glaxo Wellcome may
      elect to revert back to *** by written notice received by Deltagen at any
      time prior to its dispatch of such confirming notice.

5.2   Use.  Except as expressly provided herein, Glaxo Wellcome, directly or
indirectly through Research Partners, shall use *** and Knockout Mice solely
during the applicable Access Term (subject to Section 9.1) and solely for Glaxo
Wellcome's internal research purposes.

5.3   Transfer Fees.

      5.3.1     In partial consideration of Deltagen's resources and efforts
      expended in connection with the transfer to Glaxo Wellcome ***, Knockout
      Mice or other means of supply under Section 5.1 above, Glaxo Wellcome
      shall pay to Deltagen the following amounts at the times set forth
      herein:

           ---------------------------------------------------------------------
              By the *** in which Glaxo         *** per ***
              Wellcome receives the *** for a
              requested line of Knockout Mice,
              or Deltagen s invoice, whichever
              is later

           ---------------------------------------------------------------------
              By the *** the month in which     As mutually agreed pursuant to
              Glaxo Wellcome receives a         Section 5.1.2
              requested line of Knockout Mice
              pursuant to Section 5.1.2 or
              Deltagen s invoice, whichever is
              later

           ---------------------------------------------------------------------
              By the *** the month in which     *** per ***
              Glaxo Wellcome receives
              Deltagen s invoice after
              advising Deltagen of each
              commencement of the first
              screening activities using each
              line of Knockout Mice

           ---------------------------------------------------------------------

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -14-
<PAGE>

           ---------------------------------------------------------------------
              By the *** in which Glaxo         *** per ***
              Wellcome receives Deltagen s
              invoice after advising Deltagen
              of the *** line of Knockout Mice
              ***

           ---------------------------------------------------------------------

      5.3.2     Payments made pursuant to Section 5.3 are non-creditable and are
      non-refundable.  Payments under this Section 5.3 are in addition to any
      applicable payment under Sections 4.2 or 6.3, notwithstanding that such
      payments may relate to the same ***, Knockout Mouse and/or Product.

      5.3.3     Glaxo Wellcome will report in writing to Deltagen quarterly, ***
      using each line of Knockout Mice and each *** Knockout Mice ***, so that
      Deltagen can issue the corresponding invoice hereunder and receive payment
      without delay. Such reports will be as accurate and complete as reasonably
      possible, except that annually, Glaxo Wellcome will internally audit the
      activities giving rise to payment under Section 5.3.1 and will certify in
      writing to Deltagen, concurrently with the annual deposit into escrow
      pursuant to Section 3.4.5, the amounts due under Section 5.3.1 for each
      category of payment.  If required, the parties will make appropriate
      adjustment to true-up the payments made pursuant to Glaxo Wellcome's
      monthly reports against the amount shown on such annual certification.

      5.3.4     In the event that Glaxo Wellcome *** Knockout Mice *** in any
      ***, the parties shall meet to discuss if ***, on a going forward basis
      for the remainder *** , ***, if any, achieved by Deltagen based on the ***
      by Glaxo Wellcome and ***.

5.4   Certain Restrictions.  The transfer of ***, Knockout Mice and any other
means of supply under Section 5.1 above to Glaxo Wellcome is made expressly
subject to the following terms and conditions:

      5.4.1     Except as expressly allowed by this Agreement, all Knockout Mice
      and their progeny and *** shall remain in the sole control of Glaxo
      Wellcome and Glaxo Wellcome shall not (and shall not attempt or purport
      to) transfer such Knockout Mice, *** or mice to any Third Party.

      5.4.2     Glaxo Wellcome shall not, directly or indirectly, use or attempt
      to use the Knockout Mice ***, or any materials or information derived
      therefrom to reverse-engineer or perform any genetic manipulation on the
      Knockout Mice ***.

      5.4.3     Glaxo Wellcome shall not use or authorize or enable any Research
      Partner to use the Knockout Mice or *** and mice produced therefrom for
      any purpose other than internal research purposes for the sole benefit of
      Glaxo Wellcome.

      5.4.4     Glaxo Wellcome shall not (and shall not attempt or purport to)
      authorize or enable any Research Partner to assign, sell, have sold,
      lease, offer to sell or lease, distribute, license, sublicense or
      otherwise transfer title to or an interest the Knockout Mice and their
      progeny or ***.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -15-
<PAGE>

      5.4.5     Subject to all the terms and conditions of this Agreement, Glaxo
      Wellcome may *** to any given Research Partner (which shall, for this
      purpose, include such Research Partner's respective Affiliates) within any
      twelve (12) month period.  *** with respect to any such Research Partner
      shall require prior consultation with, and the prior written approval of,
      Deltagen (***).  All Knockout Mice *** shall be provided to Research
      Partners solely pursuant to an executed Material Transfer Agreement and
      then solely to conduct internal research at the location identified
      therein during the applicable Access Term and solely for the sole benefit
      of Glaxo Wellcome.

                                     ARTICLE 6
                                    USE OF ***

6.1   Transfer to Glaxo Wellcome.

      6.1.1     With respect to each ***, if during the applicable Access Term
      Glaxo Wellcome provides written notice to Deltagen of its desire to obtain
      *** containing such ***, Deltagen shall transfer to Glaxo Wellcome ***
      containing such *** within thirty (30) days after receiving such notice
      from Glaxo Wellcome.

6.2   Use.  Except as expressly provided herein, Glaxo Wellcome, directly or
indirectly through Research Partners, ***, and all ***, solely during the
applicable Access Term and solely for Glaxo Wellcome's internal research
purposes.

6.3   Transfer Fees.

      6.3.1     In partial consideration of Deltagen's resources and efforts
      expended in connection with the transfer to Glaxo Wellcome of *** under
      Section 6.1 above, Glaxo Wellcome shall pay to Deltagen the following
      amounts at the times set forth herein:

      --------------------------------------------------------------------------
      By the *** *** per *** in which Glaxo Wellcome receives *** from
      each *** or Deltagen's invoice whichever is
      later

      --------------------------------------------------------------------------
      By the *** in which Glaxo Wellcome receives   *** per ***
      Deltagen's invoice after advising Deltagen
      of commencement of the ***

      --------------------------------------------------------------------------
      By the *** in which an invoice is received    *** per ***
      after GW has advised Deltagen that it has
      undertaken the ***

      --------------------------------------------------------------------------

      6.3.2     Payments made pursuant to Section 6.3.1 are non-creditable and
      are non-refundable.  Payments under this Section 6.3 are in addition to
      any applicable payment under Sections 4.2

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -16-
<PAGE>

      or 5.3, notwithstanding that such payments may relate to the same ***,
      Knockout Mouse and/or Product.

      6.3.3     Glaxo Wellcome will report in writing to Deltagen, quarterly the
      commencement of *** and each undertaking of the *** promptly, so that
      Deltagen can issue the corresponding invoice hereunder and receive payment
      without delay. Such reports will be as accurate and complete as reasonably
      possible, except that annually, Glaxo Wellcome will internally audit the
      activities giving rise to payment under Section 6.3.1 and will certify in
      writing to Deltagen, concurrently with the annual deposit into escrow
      pursuant to Section 3.4.5, the amounts due under Section 6.3.1 for each
      category of payment.  If required, the parties will make appropriate
      adjustment to true-up the payments made pursuant to Glaxo Wellcome's
      monthly reports against the amount shown on such annual certification.

      6.3.4     In the event that Glaxo Wellcome ***, the parties shall meet to
      discuss if ***, on a going forward basis for the remainder ***, if any,
      achieved by Deltagen based on the *** by Glaxo Wellcome and ***.

6.4   Certain Restrictions. The transfer of the *** under Section 6.1 to Glaxo
Wellcome is made expressly subject to the following terms and conditions:

      6.4.1     Except as expressly allowed under this agreement, all *** shall
      remain in the sole control of Glaxo Wellcome and Glaxo Wellcome shall not
      (and shall not attempt or purport to) transfer any *** to any Third Party.

      6.4.2     Glaxo Wellcome shall not, directly or indirectly, use or attempt
      to use the *** to reverse-engineer or perform any genetic manipulation on
      the Knockout Mice ***. For the avoidance of any doubt Glaxo Wellcome ***.

      6.4.3     Glaxo Wellcome shall not use the *** or any *** for any purpose
      other than internal research purposes for the sole benefit of Glaxo
      Wellcome.

      6.4.4     Glaxo Wellcome shall not (and shall not attempt or purport to)
      authorize or enable any Research Partner to assign, sell, have sold,
      lease, offer to sell or lease, distribute, license, sublicense or
      otherwise transfer title to or an interest in the *** any ***.

      6.4.5     Subject to all the terms and conditions of this Agreement, Glaxo
      Wellcome may *** to any given Research Partner within any twelve (12)
      month period*** with respect to any Research Partner (which shall, for
      this purpose, include its respective Affiliates) shall require prior
      consultation with, and the prior written approval of, Deltagen (***).  All
      Knockout Mice, ***, shall be provided to Research Partners solely pursuant
      to an executed Material Transfer Agreement and then solely to conduct
      internal research at the location identified therein during the applicable
      Access Term and solely for the sole benefit of Glaxo Wellcome.

                                     ARTICLE 7
                                  CONFIDENTIALITY

7.1   Confidential Information.  During the term of this Agreement, and for a
period of fifteen (15) years following the expiration or earlier termination
hereof, each party shall maintain in

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -17-
<PAGE>

confidence all Confidential Information disclosed by the other party, and shall
not use, disclose or grant the use of the Confidential Information except on a
need-to-know basis to those directors, officers, employees, consultants,
clinical investigators, contractors, agents, distributors or permitted
assignees, to the extent such disclosure is reasonably necessary in connection
with such party's activities as expressly authorized by this Agreement.  To the
extent that disclosure is authorized by this Agreement, then prior to such
authorized disclosure, each party hereto shall obtain agreement of any such
Person to hold in confidence and not make use of the Confidential Information
for any purpose other than those permitted by this Agreement.  Each party shall
notify the other promptly upon discovery of any unauthorized use or disclosure
of the other party's Confidential Information.

7.2   Terms of this Agreement.  Except as otherwise provided in Section 7.1
above, neither party shall disclose any terms or conditions of this Agreement to
any Third Party without the prior consent of the other party.  Notwithstanding
the foregoing, prior to execution of this Agreement, the parties shall agree
upon the substance of information that can be used to describe the terms of this
transaction, and each party may disclose such information, as modified by mutual
agreement from time to time, without the other party's consent.

7.3   Permitted Disclosures.  The confidentiality obligations contained in this
Article 7 shall not apply to:- (a) the extent that the receiving party (the
"Recipient") is required (a) to disclose information by law, order or regulation
of a governmental agency or a court of competent jurisdiction, or (b) to
disclose information to any governmental agency for purposes of ***, provided in
either case that the Recipient shall provide written notice thereof to the other
party and sufficient opportunity to object to any such disclosure or to request
confidential treatment thereof.

      7.3.1     Glaxo Wellcome shall be entitled to *** generated by Glaxo
      Wellcome from Glaxo Wellcome's use of DeltaBase, the Knockout Mice and the
      *** under this Agreement, provided always that *** do not contain any
      information or data contained in DeltaBase or other Confidential
      Information of Deltagen. Glaxo Wellcome will notify Deltagen of the name
      of the ***, to allow Deltagen to satisfy itself that such publications do
      not contain any DeltaBase Information or Confidential Information of
      Deltagen. If Deltagen does not provide Glaxo Wellcome with comments upon
      any *** at least ten (10) days prior to ***, then those *** shall be
      deemed to have been approved by Deltagen. Glaxo Wellcome may submit the
      last form of *** approved (or deemed approved) by Deltagen to third
      parties for *** without requiring any further comments from Deltagen. ***
      publications shall be re-submitted to Deltagen for its review and approval
      as described in this Section 7.3.1. Any *** intended by Research Partners
      shall be subject to the provisions of section 10 of Exhibit F.

      7.3.2     Promptly upon their execution of this Agreement, the parties
      will issue the joint press release in the form attached as Exhibit G.
      Otherwise, neither party shall make any public announcement concerning
      this Agreement or the subject matter hereof, except as required by
      applicable law, without first submitting a copy of the proposed
      announcement to the other party for review and obtaining their consent
      thereto, such consent not to be unreasonably withheld or delayed.

                                      ARTICLE 8

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -18-
<PAGE>

                                   INDEMNIFICATION

8.1   Indemnity.

      8.1.1     Glaxo Wellcome shall indemnify and hold Deltagen harmless, from
      and against all losses, liabilities, damages and expenses suffered by
      Deltagen (including reasonable attorneys' fees and costs) resulting from
      all claims, demands, actions and other proceedings by any Third Party to
      the extent arising from (a) a material breach of any representation,
      warranty or covenant of Glaxo Wellcome under this Agreement, (b) the use
      of the DeltaBase, Knockout Mice or *** by or for Glaxo Wellcome, (c) the
      development, manufacture, possession, distribution, use, testing, sale or
      other disposition of any Product (without regard to culpable conduct), or
      (d) the *** or its Research Partners in the performance of its
      obligations, and its permitted activities, under this Agreement.

      8.1.2     Deltagen shall indemnify and hold Glaxo Wellcome harmless, from
      and against all losses, liabilities, damages and expenses suffered by
      Glaxo Wellcome (including reasonable attorneys' fees and costs) resulting
      from all claims, demands, actions and other proceedings by any Third Party
      to the extent arising from (a) a material breach of any representation,
      warranty or covenant of Deltagen under this Agreement  , or (b) *** *** in
      the performance of its obligations to be performed under this Agreement.

8.2   Procedure.  A party (the "Indemnitee") that intends to claim
indemnification under this Article 8 shall promptly notify the other party (the
"Indemnitor") of any claim, demand, action or other proceeding for which the
Indemnitee intends to claim such indemnification.  The Indemnitor shall have the
right to participate in, and to the extent the Indemnitor so desires jointly
with any other indemnitor similarly notified, to assume the defense thereof with
counsel selected by the Indemnitor; provided, however, that the Indemnitee shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the Indemnitor, if representation of the Indemnitee by the counsel retained
by the Indemnitor would be inappropriate due to actual or potential differing
interests between the Indemnitee and any other party represented by such counsel
in such proceedings.  The indemnity obligations under this Article 8 shall not
apply to amounts paid in settlement of any claim, demand, action or other
proceeding if such settlement is effected without the prior express written
consent of the Indemnitor, which consent shall not be unreasonably withheld or
delayed.  The failure to deliver notice to the Indemnitor within a reasonable
time after notice of any such claim or demand, or the commencement of any such
action or other proceeding, if prejudicial to its ability to defend such claim,
demand, action or other proceeding, shall relieve such Indemnitor of any
liability to the Indemnitee under this Article 8 with respect thereto, but the
omission so to deliver notice to the Indemnitor shall not relieve it of any
liability that it may have to the Indemnitee otherwise than under this
Article 8.  The Indemnitor may not settle or otherwise consent to an adverse
judgment in any such claim, demand, action or other proceeding, that diminishes
the rights or interests of the Indemnitee without the prior express written
consent of the Indemnitee, which consent shall not be unreasonably withheld or
delayed.  The Indemnitee, its employees and agents, shall reasonably cooperate
with the Indemnitor and its legal representatives in the investigation of any
claim, demand, action or other proceeding covered by this Article 8.

8.3    Insurance.  Each party shall maintain with a reputable insurance company
such

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -19-
<PAGE>

comprehensive general liability insurance coverage with respect to their
respective obligations and liabilities under this Agreement as it determines
reasonable and appropriate for its respective business and activities.

                                     ARTICLE 9
                                    TERMINATION

9.1   Term.  The term of this Agreement shall commence on the Effective Date and
continue thereafter unless terminated earlier pursuant to this Article 9. This
Agreement in so far as it relates to Glaxo Wellcome's access to and use of
Knockout Mice, *** and DeltaBase shall expire on the expiry of the Access Term.
Subject to Section 9.6.2, the right of Glaxo Wellcome to develop, make, have
made, use, offer for sale, sell, import and keep Products under *** shall
continue in full force and effect notwithstanding ***; provided always that
Glaxo Wellcome complies with all the payment and other applicable and relevant
provisions of this Agreement.

9.2   Termination for Cause.  A party may terminate this Agreement upon or after
the breach of any material provision of this Agreement (which shall include,
without limitation, any material breach by Deltagen of *** and any material
breach by Glaxo Wellcome of its *** by the other party, if the breaching party
has not cured such breach within *** after written notice thereof from the other
party.  Notwithstanding the foregoing, in the case of a failure to pay any
undisputed amounts due hereunder the period of cure of any such default shall be
*** and, unless payment is made within such period, the termination shall become
effective at the end of such *** period.

9.3   Termination on Notice. Glaxo Wellcome shall be entitled to terminate this
Agreement, without the necessity of good cause, upon the service on Deltagen, at
any time during the *** next following the first anniversary of the Effective
Date, of written notice of termination pursuant to this Section 9.3 plus
payment, concurrently with such notice, of an amount equal to ***  under Section
3.2.1) plus all of Glaxo Wellcome's unpaid payment obligations incurred up to
the date of termination.  Termination pursuant to this Section 9.3 shall be
effective *** Deltagen's receipt of such notice.

9.4   Termination on Insolvency. Either party may terminate this Agreement upon
the other party (a) passing a resolution for its winding-up or a court of
competent jurisdiction making an order for that party's winding-up or
dissolution or (b) the making of an administration order in relation to that
party or (c) the appointment of a receiver over, or an encumbrancer taking
possession of or selling an asset of, that party or (d) the other party making
an arrangement or composition with its creditors generally or making an
application to a court of competent jurisdiction for protection from its
creditors generally.

9.5   ***.

      9.5.1     Either party may terminate this Agreement for good reason,
      determined reasonably and in good faith, in the event that the other party
      completes any transaction for the sale or transfer to a Third Party of
      substantially all of the other party's business (by asset or stock sale,
      merger or otherwise).  For the purposes of this Section 9.5.1, "***"
      includes if such Third Party is ***. Deltagen expressly consents to the
      merger between Glaxo Wellcome and

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -20-
<PAGE>

      SmithKline Beecham and that, if completed, the provisions of this
      Agreement shall apply to the newly merged entity, provided that the newly
      merged entity executes an assumption agreement, in form reasonably
      satisfactory to Deltagen, pursuant to which the newly merged entity
      assumes all of Glaxo Wellcomes obligations and liabilities hereunder upon
      identical terms and conditions to those set out in this Agreement.

      9.5.2     Glaxo Wellcome may terminate this Agreement without the
      necessity of good reason, in the event that Glaxo Wellcome completes any
      transaction for the sale or transfer to a Third Party of substantially all
      of such party's business (by asset or stock sale, merger or otherwise).

      9.5.3     For the avoidance of doubt, this Section 9.5 does not apply to
      an initial public offering or any other public sale of securities, a
      corporate reorganization, the sale of securities in a financing or
      re-financing, or any other similar transaction.

      9.5.4     A termination pursuant to this Section 9.5 by a party shall
      occur, if at all, by prompt written notice to the other party (a) in the
      case of a termination under section 9.5.1, within thirty (30) days after
      receipt of written notice from the other party of the pendency or
      completion of the pertinent transaction and (b) in the case of a
      termination under Section 9.5.2, within five (5) days after the completion
      of the pertinent transaction.

9.6   Effect of Expiration and Termination.

      9.6.1     Termination or expiration of this Agreement shall not relieve
      either party hereto from any obligation to make payment or other liability
      accruing prior to such termination or expiration, nor preclude either
      party from pursuing any rights and remedies it may have hereunder in law
      or equity which accrued or are based upon any event occurring prior to
      such termination or expiration.

      9.6.2     Upon termination of this Agreement by Glaxo Wellcome pursuant to
      Sections 9.3 or 9.5 or any termination by Deltagen pursuant to Sections
      9.2 or 9.4, all rights and licenses granted by or under this Agreement, in
      respect of Products for which Glaxo Wellcome has not completed all its
      payment obligations as set out in this Agreement that have come due prior
      to such termination date, shall immediately terminate and Glaxo Wellcome
      shall, and shall cause its Research Partners to, (i) immediately
      discontinue all access to and use of the DeltaBase, the Knockout Mice,
      ***; (ii) purge the DeltaBase from all computers within its possession or
      control and otherwise remove the DeltaBase from the Installation Sites;
      (iii) return to Deltagen or destroy the DeltaBase (except for one (and
      only one) copy in object code form which may be retained, uninstalled, by
      counsel to Glaxo Wellcome on magnetic media solely for legal archive
      purposes), all remaining Knockout Mice, ***, and all information, data,
      progeny, materials, and other compositions derived therefrom and copies
      thereof; and (iv) for each Installation Site and on behalf of Glaxo
      Wellcome and its Research Partners generally, provide an express written
      certification by a responsible officer of GWRD that items (i) through
      (iii) above have been fully complied with within thirty (30) days after
      the date of such termination or expiration. For the avoidance of any doubt
      *** (under which Glaxo Wellcome has completed all of such relevant
      payments), shall continue in full force and effect *** but subject to
      Glaxo Wellcomes continued compliance with all the terms and conditions of
      this Agreement as they apply to ***.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -21-
<PAGE>

      9.6.3     Upon any termination by Glaxo Wellcome pursuant to Sections 9.2
      or 9.4 or by Deltagen pursuant to Section 9.5.1, all rights and licenses
      granted by or under this Agreement, in respect of *** for which Glaxo
      Wellcome has either completed or chooses to continue its payment
      obligations as set out in Section ***, will continue on the terms and
      conditions set forth in this Agreement (including regarding payment), but
      shall be *** received by Glaxo Wellcome through the date of such
      termination.  The survival of such *** pursuant to this Section 9.6.3
      shall remain subject to Section 9.6.2 upon subsequent termination of this
      Agreement as so limited, by the applicable party.

      9.6.4     The provisions of Articles 1, 7, 8, 9, 10 (excluding Section
      10.2), 12 and 14; the provisions of Sections 2.6, 2.7, 2.8, 3.4.1,
      3.4.2.2, 3.4.2.3, 3.4.3, 3.4.5, 4.4, 4.6, 5.4, 6.4 11.1 and 11.5; and, to
      the extent applicable, all provisions regarding payment due hereunder
      shall survive any expiration or termination of this Agreement.

                                     ARTICLE 10
                                   MISCELLANEOUS

10.1  Compliance with Law.  Glaxo Wellcome shall be responsible for compliance
with all applicable product safety, product testing, product labeling, package
marking, and product advertising laws and regulations with respect to its own
activities and products (including Products).  Further, Glaxo Wellcome shall
comply with the laws and regulations of the United States and any other relevant
nation concerning any export or transfer of technology, services or products.

10.2  Joint Committee. Within ten days after the Effective Date, GWRD, on behalf
of Glaxo Wellcome, and Deltagen each shall designate their respective
representatives on a Joint Committee; each party shall nominate *** to serve on
the Joint Committee and may replace said representative(s) from time-to-time by
written notice to the other party. On an annually rotating basis, one of the
party's representatives shall be the Chair of the Joint Committee and one of the
other party's representatives shall be the Secretary of the Joint Committee,
with ***. The Joint Committee shall meet at the minimum on a *** basis during
the Access Term, unless the parties agree otherwise, and shall be (a)
responsible for the supervision of the installation of the DeltaBase and the
procedures relating to access to the DeltaBase by Glaxo Wellcome in accordance
with this Agreement and (b) an initial forum for the *** under this Agreement.
Each party shall bear their own costs and expenses incurred in supporting the
Committee and meetings shall take place as decided at each meeting of the
Committee. All actions by the Joint Committee shall require the unanimous vote
of all representatives, and the Joint Committee shall have quorum requirement of
at least one (1) representative of each party present and voting. Subject to the
last sentence of Section 10.5, actions and decisions by *** vote of the Joint
Committee shall be binding on both parties; provided, however, that although the
Joint Committee may, subject to Section 10.9, waive the application of a
particular provision of this Agreement to a particular situation on a case-by-
case basis, it shall not have the power or the authority to amend this Agreement
and any such amendment shall be effective only upon full execution of a formal
instrument of amendment pursuant to Section 10.5. In the event that the
Committee does not reach agreement in relation to any decisions the matter shall
be resolved by further negotiation or, if applicable, dispute resolution in
accordance with Article 12. Meetings shall take place at such location and may
be held in person, by telephone or by video conference, as the Joint

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -22-
<PAGE>

Committee may agree.

10.3  Notices.  Any consent, notice or report required or permitted to be given
or made under this Agreement by one of the parties to the other shall be in
writing and addressed to such other party at its address indicated below, or to
such other address as the addressee shall have last furnished in writing to the
addressor, and shall be effective upon receipt by the addressee.

      If to Deltagen:     Deltagen, Inc.
                          1003 Hamilton Avenue
                          Menlo Park, CA  94025
                          U.S.A.
                          Attention: President

                          With a copy to: General Counsel, at the same address

                                         -23-
<PAGE>

      If to Glaxo Wellcome:    Glaxo Group Limited
                               Glaxo Wellcome House
                               Berkeley Avenue
                               Greenford
                               UK
                               UB6 ONN
                               Attention:  The Company Secretary

10.4  Assignment.  Except as otherwise expressly provided under this Agreement,
neither this Agreement nor any right or obligation hereunder may be assigned or
otherwise transferred (whether voluntarily, by operation of law or otherwise),
without the prior express written consent of the other party; * * *.  Any
permitted assignee shall assume all obligations of its assignor under this
Agreement.  Any purported assignment or transfer in violation of this Section
10.4 shall be void.

10.5  Applicable Law.  This Agreement shall be governed by and construed in
accordance with the laws of * * *, without regard to the conflicts of law
principles thereof.

10.6  Entire Agreement.  This Agreement contains the entire understanding of the
parties with respect to the subject matter hereof.  All express or implied
representations, agreements and understandings, either oral or written,
heretofore made are expressly superseded by this Agreement.  This Agreement may
be amended, or any term hereof modified, only by a written instrument duly
executed by both parties.

10.7  Headings.  The captions to the several Articles and Sections hereof are
not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Articles and Sections hereof.

10.8  Independent Contractors.  Each party hereby acknowledges that the parties
shall be independent contractors and that the relationship between the parties
shall not constitute a partnership, joint venture or agency.  Neither party
shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other party,
without the prior consent of the other party to do so.

10.9  Waiver.  The waiver by a party of any right hereunder, or of any failure
to perform or breach by the other party hereunder, shall not be deemed a waiver
of any other right hereunder or of any other breach or failure by the other
party hereunder whether of a similar nature or otherwise.

10.10 Force Majeure.  A party shall neither be held liable or responsible to the
other party, nor be deemed to have defaulted under or breached this Agreement,
for failure or delay in fulfilling or performing any obligation under this
Agreement (other than an obligation for the payment of money) to the extent, and
for so long as, such failure or delay is caused by or results from causes beyond
the reasonable control of such party including but not limited to fire, floods,
embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotion, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the
other party.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -24-
<PAGE>

10.11 Other Activities.  Except as otherwise expressly provided in this
Agreement, nothing in this Agreement shall preclude either party from conducting
other programs (either for its own benefit or with or for the benefit of any
other Person) to conduct research, or to develop or commercialize products or
services, for use in any field.

10.12 LIMITATION OF LIABILITY.  EXCEPT AS PROVIDED OTHERWISE IN THIS AGREEMENT
IN ARTICLE 8 OR IN THE EVENT OF A MATERIAL BREACH OF SECTIONS 3.3 OR 3.4.2 OR A
BREACH OF ARTICLE 7, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY
FOR CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR EXEMPLARY DAMAGES OF ANY
KIND, INCLUDING WITHOUT LIMITATION LOSS OF PROFITS, SAVINGS OR REVENUE, OR THE
CLAIMS OF THIRD PARTIES, WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH
LIABILITY OR LOSS, HOWSOEVER CAUSED, AND ON ANY THEORY OF LIABILITY, RELATING TO
OR IN CONNECTION WITH THIS AGREEMENT.

10.13 Joint and Several Liability.  GGL and GWRD shall be jointly and severally
liable for all obligations and liabilities of Glaxo Wellcome and its Research
Partners under this Agreement.

10.14 Counterparts.  This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

                                     ARTICLE 11
                               INTELLECTUAL PROPERTY

11.1  Ownership of Intellectual Property Rights.

      11.1.1    With the exception of the rights and licenses to Glaxo
      Wellcome pursuant to Article 4 and subject to Section 11.1.2, Deltagen
      shall solely own and retain all rights, title and interests and all
      intellectual property and intellectual property rights in and to Deltagen
      Patent Rights, DeltaBase, Knockout Mice, * * *, together with all
      Derivative Works thereof and all results, modifications and inventions
      thereto or arising therefrom made or derived by or on behalf of Deltagen.

      11.1.2    Subject to the prior rights of Deltagen under Section 11.1.1 and
      any of Deltagen's other intellectual property and intellectual property
      rights, including any rights it may have in Derivative Works as noted in
      Section 11.1.4, Glaxo Wellcome shall solely own and retain all rights,
      title and interests in and to any * * * and all results, modifications and
      inventions made by or on behalf of Glaxo Wellcome arising from its access
      to the Deltagen Proprietary Information and/or research using Knockout
      Mice, * * * in accordance with this Agreement including, * * * provided
      hereunder or any Products that may arise from such research.

      11.1.3    Subject to the prior rights of Deltagen under Section 11.1.1 and
      any of Deltagen's other intellectual property and intellectual property
      rights, including any rights it may have in * * * as noted in Section
      11.1.4, the parties shall jointly own any * * * and results, inventions
      and modifications that (a) are co-invented (in the case of patentable
      subject matter), jointly * * *) and/or jointly or co-developed/created (in
      the case of trade secrets), in each case as determined under applicable
      law, and (b) arise from Glaxo Wellcome's access to and use of

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -25-
<PAGE>

      the Deltagen Proprietary Information and/or research using Knockout
      Mice ***. In the event of any such joint ownership of intellectual
      property and intellectual property rights, the parties shall negotiate
      in good faith about how best to exploit such intellectual property
      rights.

      11.1.4    Glaxo Wellcome's sole or joint ownership rights in any * * * and
      results, modifications and inventions described in Sections 11.1.2 or
      11.1.3 shall not affect Deltagen's or a third party's ownership of and
      prior rights in the underlying work from or on which such * * * or
      results, modifications and inventions is derived.

11.2  Infringements.  In the event that Glaxo Wellcome becomes aware of a
product or activity which it believes to infringe a Valid Claim of the Deltagen
Patent Rights* * * but shall promptly advise Deltagen of all relevant facts and
circumstances known to it in connection with such infringement. Deltagen * * *
during the Access Term (and whilst any licences granted pursuant to Section 4.1
remain in effect) of (a) * * * and (b) of all infringements, claims, judgments
or settlements against or owed by Deltagen, or any claims or arbitration,
mediation and/or litigation * * *.

11.3  Patent Prosecution.  Deltagen shall at its sole discretion and expense,
have the sole right (but not the obligation) to prosecute, maintain, abandon
and enforce any and all of the Deltagen Patent Rights as and to the extent
solely Deltagen determines appropriate. Deltagen shall * * * that is part of
the Deltagen Patent Rights and covering a *** or a Knockout Mouse, ***
provided hereunder. Upon request, Deltagen will reasonably inform Glaxo
Wellcome, in confidence if applicable, * * *.

11.4  No Challenge. In consideration of * * * to, challenge or contest or seek
to invalidate or otherwise block any of the Deltagen Patent Rights or the
issuance or enforcement of any patent or Valid Claim of the Deltagen Patent
Rights. If, following the expiry of the Access Term, Glaxo Wellcome or any Third
Party on behalf of Glaxo Wellcome acts in contravention of this Section 11.4,
Deltagen shall be entitled to terminate *** pursuant to Section 4.1 which is
covered by the Deltagen Patent Right which Glaxo Wellcome seeks to challenge or
contest.

11.5  No Implied Licenses. Notwithstanding anything to the contrary in this
Agreement, Deltagen retains all of its right, title and interest in and to the
Deltagen Patent Rights, the DeltaBase, the Excluded Patent Rights, * * *, the
Knockout Mice, * * * and all other intellectual property rights of Deltagen, the
* * * Glaxo Wellcome shall be limited to those expressly set forth in this
Agreement, and no grants or licenses of rights to Glaxo Wellcome, its Research
Partners or any Third Party shall be implied.  Except as expressly permitted
hereby, Glaxo Wellcome shall not use, practice, modify, reproduce, distribute,
or otherwise transfer or exploit any of the DeltaBase, the Deltagen Patent
Rights, the Excluded Patent Rights, * * *, the Knockout Mice, * * * or any other
intellectual property rights of Deltagen, in whole or in part.

                                     ARTICLE 12
                                 DISPUTE RESOLUTION

12.1  Mediation.

      12.1.1    Any dispute, controversy or claim arising out of or relating to
      this Agreement, or the interpretation, breach, termination or validity
      hereof, shall be resolved in the first instance

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -26-
<PAGE>

      through consultation.  Such consultation shall begin promptly after one
      party has delivered to the other party a written request for such
      consultation.

      12.1.2    If within 30 days following the date on which a request for
      consultation described in Section 12.1.1 is given the dispute cannot be
      resolved, the parties shall seek to settle it by mediation in accordance
      with the Centre for Dispute Resolution ("CEDR") Model Mediation Procedure
      (the "Model Procedure").  To initiate a mediation a party must give notice
      in writing to the other party to the dispute requesting a mediation
      pursuant to this Section 12.1.2.  A copy of the request shall also be sent
      to CEDR.  The mediation shall be before a single, jointly agreed upon,
      mediator.  If the parties are unable to select a mutually agreeable
      mediator within * * * after the initiation of mediation, then
      participation in such mediation is not required and Section 12.3 shall
      apply.

      12.1.3    The mediation shall take place at a time and neutral location
      selected by the mediator after due consultation with the parties.
      Statements made during the mediation and all submissions to the mediator
      shall be confidential and shall be treated as settlement discussions and
      not be admissible in evidence in any court proceeding. Any applicable
      statute of limitations shall be tolled during the period from the
      initiation of mediation proceedings until thirty (30) days after the
      cessation thereof.

      12.1.4    The procedure in the Model Procedure will be amended to take
      account of any relevant provisions in this Agreement and any other
      agreement which the parties may enter into in relation to the conduct of
      the mediation.

      12.1.5    The commencement of a mediation shall be within twenty eight
      (28) days of the service of the notice set out in Section 12.1.2, and
      subject to Sections 12.2 and 12.3 neither party shall commence with court
      proceedings until they have attempted to settle the dispute by mediation
      in accordance with this Article 12.

12.2  Equitable Remedies.  Nothing in this Article 12 shall prevent or limit a
party from seeking an injunction or other equitable relief to prevent breaches
of Article 7 or, in the case of actions brought by Deltagen, to restrain Glaxo
Wellcome or a Research Partner from use of DeltaBase, or any Knockout Mouse, ***
in a manner or to an extent not authorized by this Agreement.

12.3  Court Proceedings.  If a mediation cannot commence because the parties are
unable to agree jointly on a mediator (see the last sentence of Section 12.1.2),
or if a meditation commences but the dispute(s), controversy(ies) or claim(s) in
question are not fully resolved by the mediation process within * * *
thereafter, then either party is fully free to pursue through court proceedings
any or all rights and remedies it may have.

                                     ARTICLE 13
                                MOST FAVOURED NATION

13.1  More favorable Terms.  In the event that Deltagen enters into an agreement
with any of its subscribers to DeltaBase that * * * to Deltagen, * * *, which
are * * * to Deltagen, * * *, set out in this Agreement, then Deltagen and Glaxo
Wellcome shall enter into a separate confidentiality agreement and Deltagen
shall notify named individuals within  Glaxo Wellcome

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -27-
<PAGE>

promptly of the * * * and Glaxo Wellcome shall have * * * to determine whether
to * * * or not. In particular, if the * * * provided under a DeltaBase
subscription is * * *, Deltagen shall (as described above) notify Glaxo Wellcome
of the * * * so that Glaxo Wellcome may decide whether * * * of this Section 13
or not.

                                     ARTICLE 14
                                  WITHHOLDING TAX

14.1  Payment Without Deduction.  All payments due under this Agreement will be
made in full without deduction for or on account of any present or future taxes
or duties of whatever nature that may be imposed, except as provided in Section
14.2

14.2  Withholding Taxes.  Glaxo Wellcome * * * from amounts otherwise due
hereunder if and as compelled by applicable law and shall remit the amount
withheld to the appropriate taxing authorities on Deltagen's behalf and the
remainder to Deltagen.  Glaxo Wellcome will provide Deltagen with a written
receipt or a tax deduction certificate from the tax authority for all taxes so
withheld. Glaxo Wellcome will cooperate with Deltagen in obtaining exemption
from such withholding and in minimizing or avoiding any such tax withholding
requirement, as available under applicable law.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -28-
<PAGE>

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first set forth above.

                               DELTAGEN, INC.

                               By:  /S/ William Matthews
                                   ------------------------

                               Title: President and Chief Executive Officer
                                      -------------------------------------

                               GLAXO GROUP LIMITED

                               By:  /s/ F. M. Bicknell
                                   ---------------------------

                               Title: Assistant Corporate Secretary
                                      -------------------------------

                               GLAXO RESEARCH AND DEVELOPMENT LIMITED

                               By:  /s/ F. M. Bicknell
                                   -----------------------

                               Title: Corporate Secretary
                                     ---------------------

                                         -29-
<PAGE>

                                     EXHIBIT E

                                  ESCROW AGREEMENT

The parties have established the following escrow procedures to facilitate (a) a
means by which the parties can fulfill their obligations under this Agreement
and (b) a means of notification to Deltagen that certain payments under this
Agreement are to be made by Glaxo Wellcome to Deltagen, while providing for
increased anonymity of Glaxo Wellcome's research and development activities.

1.    Within * * * after Glaxo Wellcome's receipt of each Phenotype Set Glaxo
      Wellcome shall perform the following actions in this Section 1.  With
      respect to each Target Gene in each such Phenotype Set, Glaxo Wellcome
      shall generate a unique Glaxo gene identification number ("Glaxo Gene ID
      Number") that corresponds to each Deltagen gene identification number
      ("Deltagen Gene ID Number") for each Target Gene.  Glaxo Wellcome shall
      then make a deposit into escrow in its annual escrow deposit of a written
      key in tabular form that lists each Glaxo Gene ID Number paired and
      identified with the corresponding Deltagen Gene ID Number. Glaxo Wellcome
      shall also provide Deltagen in writing each year in an annual report with
      each set of Glaxo Gene ID Numbers deposited into escrow, identifying the
      Phenotype Set corresponding to such Glaxo Gene ID numbers.  Upon such
      deposit into escrow, Glaxo Wellcome shall then have the right to use the
      DeltaBase Information with respect to such Designated Gene for use in
      accordance with the terms and conditions of this Agreement.  Any use of
      such DeltaBase Information not in conformance with this Agreement is
      expressly prohibited.

2.    Glaxo Wellcome shall make a deposit into escrow in its annual escrow
      deposit of each Glaxo Gene ID Number intended to be used in the conduct of
      research or development by Glaxo Wellcome.  Such deposit shall also
      include the first date of use or planned use of such Target Gene.  Any
      escrow deposits shall be made by Glaxo Wellcome to an escrow agent
      mutually agreed to in writing between the parties ("Escrow Agent").  Such
      Escrow Agent shall be a reputable law firm based in London.  The Escrow
      Agent may be changed upon the written request of a party and the
      acceptance of the other party, which acceptance shall not be unreasonably
      withheld.

3.    Promptly upon PRE-CLINICAL CANDIDATE SELECTION under Section 4.2 of this
      Agreement, Glaxo Wellcome shall make a deposit into escrow in its annual
      escrow deposit of the Deltagen Gene ID Number corresponding to each Target
      Gene with respect to which Glaxo Wellcome commences PRE-CLINICAL CANDIDATE
      SELECTION under Section 4.2 of this Agreement.  Glaxo Wellcome shall also
      notify Deltagen in writing each year in an annual report of the Glaxo Gene
      ID number for each such Target Gene.

4.    With respect to each payment of * * * under Section 5.3.1 of this
      Agreement, Glaxo Wellcome shall make a deposit into escrow in its annual
      escrow deposit of the Deltagen Gene ID Number corresponding to Target
      Gene/Knockout Mouse line that is the subject of such payment.  Glaxo
      Wellcome shall also notify Deltagen in writing each year in an annual
      report of the Glaxo Gene ID number for each such Target Gene/Knockout
      Mouse line.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -30-
<PAGE>

5.    With respect to each payment of * * * for (a) * * * and (b) * * * with
      respect to each ***, under Section 6.3.1 of this Agreement, Glaxo
      Wellcome shall, in its annual escrow deposit, make a deposit into
      escrow of the Deltagen Gene ID Number corresponding to Target Gene/ES
      Cell line that is the subject of such payment.  Glaxo Wellcome shall
      also notify Deltagen in writing each year in an annual report of the
      Glaxo Gene ID number for each such Target Gene/ES Cell line.

6.    All information or data deposited with the Escrow Agent shall be deposited
      via electronic mail using a public key cryptography system reasonably
      acceptable to Glaxo Wellcome and Escrow Agent.  The Escrow Agent will
      promptly copy the received decrypted information onto a CD-ROM, recorded
      with the date and time and reasonably explaining the purpose of the
      deposit as it relates to the specific escrow deposit requirements under
      this Agreement.  A back-up copy of such information shall be maintained in
      a fireproof safe (or other similar fireproof method) by the Escrow Agent.
      The Escrow Agent shall notify Deltagen in writing (with a written copy to
      Glaxo Wellcome) each time an escrow deposit is made by Glaxo Wellcome.

7.    In the event that Deltagen reasonably believes in good faith that payments
      are due and payable under this Agreement and Glaxo Wellcome has not paid
      such payments to Deltagen, Deltagen shall have the right to request from
      Glaxo Wellcome, * * *, a written declaration of intent to make such
      payments.  Such request may include a request that Glaxo Wellcome prepare
      a reasonably detailed written accounting of the Glaxo Gene ID Numbers and
      a summary of the current status of research or development with respect to
      the disputed payment(s).  Glaxo Wellcome shall have * * * to respond in
      writing to Deltagen's request.  If Deltagen is not reasonably satisfied
      with the response, Glaxo Wellcome shall, within * * * written notice from
      Deltagen, make a deposit into escrow of the written accounting and
      summary.  Deltagen shall have the right to have an independent third party
      reasonably acceptable to Glaxo Wellcome, perform an audit of the files and
      deposited materials of the Escrow Agent corresponding to the disputed
      payment.  Such third party shall report to Deltagen only whether Glaxo
      Wellcome is in compliance with the applicable terms and conditions of this
      Agreement.

8.    The fees of the Escrow Agent will be borne by * * *.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -31-
<PAGE>

                                     EXHIBIT F

                        FORM OF MATERIAL TRANSFER AGREEMENT

NB.  The parties acknowledge that this draft shall form the basis of any MTA and
that any material changes requested by a Third Party shall require the prior
approval of both Glaxo Wellcome and Deltagen.

      THIS * * * MATERIALS TRANSFER AGREEMENT (this "Agreement") dated as of
___________, 200__ (the "Effective Date"), is entered into between Glaxo
Research and Development Limited, a United Kingdom limited company ("Glaxo
Wellcome"), having a place of business at Glaxo Wellcome Medicines Research
Centre, Gunnells Wood, Stevenage, SG1 2NY United Kingdom, and
_____________________________, a _________________________ (the "Research
Partner", located at __________________________.  The parties hereby agree as
follows:

1.    For purposes of this Agreement, the "Materials" shall mean the * **
      materials listed in Exhibit A, together with (a) all * * *, and (b) all *
      * * and (c) any information that is  required to be provided to the
      Research Partner concerning the use of the * * * materials.

2.    Glaxo Wellcome is willing to transfer to the Research Partner the
      Materials and permit the Research Partner to access the Materials on the
      terms and conditions of this Agreement.

3.    The Research Partner shall use the Materials for the sole purpose of
      conducting the research (the "Research") described in Exhibit B for Glaxo
      Wellcome, and not for any other purpose or for or the benefit of any other
      person or entity.  The Research Partner shall not use the Materials in any
      research that is subject to consulting or licensing obligations to another
      corporation or a government agency.  Nothing herein shall be construed to
      grant any rights to the Research Partner under any patent, patent
      application or other intellectual property rights, other than for the sole
      purpose of conducting the Research.  The Research Partner shall use the
      Materials in compliance with (i) generally accepted * * * standards for
      non-clinical research and laboratory animal care and welfare as reasonably
      implemented by the Research Partner in its facilities and operations, and
      (ii) * * *. THE  RESEARCH PARTNER UNDERSTANDS THAT THE MATERIALS ARE FOR
      RESEARCH USE ONLY AND HAVE NOT BEEN APPROVED FOR HUMAN USE.  THE RESEARCH
      PARTNER SHALL NOT ADMINISTER THE MATERIALS TO HUMANS IN ANY MANNER OR
      FORM.

4.    The Research Partner shall not transfer or disclose the Materials to any
      person or entity, other than Glaxo Wellcome, not under the direct control
      of the Research Partner.

5.    As between the Research Partner and Glaxo Wellcome, all right, title and
      interest in and to all Materials shall be solely owned by Glaxo Wellcome.
      The Research Partner hereby irrevocably assigns to Glaxo Wellcome or its
      designee, any right, title and interest it may otherwise acquire in or to
      the Materials. Glaxo Wellcome shall retain, and Research Partner hereby
      assigns to Glaxo Wellcome all right, title and interest in and to any and
      all

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -32-
<PAGE>

      discoveries, inventions and other subject matter, whether patentable or
      not (collectively, "Inventions"), conceived, reduced to practice or
      otherwise discovered by the Research Partner in connection with its use of
      the Materials as permitted under this Agreement, and all intellectual
      property rights therein. Research Partner agrees to promptly report to
      Glaxo Wellcome all Inventions.

6.    Upon completion of the Research, the Research Partner shall cease all use
      and make no further use of the Materials.  The Research Partner shall take
      all reasonable steps including but not limited to those steps taken to
      protect information and other property of its own of a confidential
      nature, to insure that the Materials and information received from Glaxo
      Wellcome are not disclosed, duplicated or in any manner delivered or
      disseminated to others.

7.    The Research Partner hereby acknowledges that the Materials are
      experimental in nature and are provided "AS IS" AND WITHOUT ANY
      REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT
      LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY
      PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT
      INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD
      PARTY.

8.    In no event shall Glaxo Wellcome, Deltagen, Inc., a Delaware corporation
      ("Deltagen") or their respective Affiliates be liable for any use of the
      Materials by the Research Partner, including any use developed by the
      Research Partner.  The Research Partner shall indemnify and hold harmless
      Glaxo Wellcome, Deltagen and their respective officers, directors,
      employees and agents against any and all losses, liabilities, damages and
      expenses (including reasonable attorneys' fees and costs) incurred in
      connection with any claims, demands, actions or other proceedings which
      may arise from or be connected with any use, handling or storage of the
      Materials by the Research Partner.

9.    The Research Partner shall not enforce (or attempt to purport to enforce)
      against Glaxo Wellcome, Deltagen or their respective Affiliates,
      Deltagen's subscribers to all or any part of the DeltaBase (that provide a
      similar covenant to Glaxo Wellcome) or licensees of any intellectual
      property rights of Deltagen (that provide a similar covenant to Glaxo
      Wellcome) any patent that claims (or purports to claim) (a) any mice
      (including * * * mice), (b) any * * * (including * * * mice), (c) any * *
      * (including * * * genes), (d) any * * *, (e) any * * * with respect to
      such mice, * * *, (f) any methods or processes regarding database
      generation or information processing, or (g) any research or development
      use of such mice, * * *, database generation, information processing or
      information.

10.   The Research Partner will provide Glaxo Wellcome with regular updates of
progress and a report describing the results of the proposed investigations. No
publications reporting studies using the Materials shall be published or
otherwise disclosed unless such proposed publications are sent to Glaxo Wellcome
and Deltagen for review and approval 90 days prior to their proposed submission
date for publication or such other disclosure. If Glaxo Wellcome and/or Deltagen
determines that the proposed publication contains possible patentable subject
matter or Glaxo Wellcome and/or Deltagen confidential information, Glaxo
Wellcome or Deltagen may

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -33-
<PAGE>

delay the publication, while adequate protection is obtained and/or confidential
information is deleted.  Authorship will be determined by the relative
contributions of each party to the work performed using the Materials. All these
publications will acknowledge Glaxo Wellcome and/or Deltagen as the source of
the Materials.

11.   The Materials are subject to a non exclusive license agreement between
Glaxo Wellcome (and/or its Affiliate) and Deltagen and constitute wholly or in
part the proprietary property of Deltagen.  Consequently, Deltagen shall be
considered to be a third party beneficiary of this Agreement.

12.   This Agreement represents the entire agreement between the parties
regarding the subject matter hereof and shall supersede all previous
communications, representations, understandings and agreements, whether oral or
written, by or between the parties with respect to the Materials.

13.   This Agreement shall have effect for a period of * * * from the date of
signature and shall then terminate unless extended for a further period or
periods by the written agreement of both parties.  Clauses 3, 4, 5, 6 and 7
shall survive termination of this Agreement.  On termination any remaining
Materials will be destroyed or returned to Glaxo Wellcome as Glaxo Wellcome
decides.

14.   This Agreement shall be governed by and construed in accordance with the
laws of England and Wales and the parties hereto submit to the exclusive
jurisdiction of the English courts.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -34-
<PAGE>

      IN WITNESS WHEREOF, the parties have entered into this Agreement as of the
date first written above.

                                    ----------------------------------
                                    By:
                                         -----------------------------
                                    Title:
                                          ----------------------------

                                    GLAXO RESEARCH AND DEVELOPMENT LIMITED

                               By:
                                         -----------------------------
                                    Title:
                                         -----------------------------

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                         -35-
<PAGE>

                                     EXHIBIT A

                                     MATERIALS

                                 [TO BE COMPLETED]

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

<PAGE>

                                     EXHIBIT B

                                      RESEARCH

                                 [TO BE COMPLETED]

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                       -37-
<PAGE>

                                     EXHIBIT G

                            AGREED FORM OF PRESS RELEASE

The parties agree that a suitable and mutually agreed upon press release shall
be made by Deltagen or Glaxo Wellcome as soon as possible after execution of
this Collaboration Agreement.  If the press release is to be made by Glaxo,
Glaxo shall have the right to delay the press release until the expiration of
the "quiet period" that Deltagen is subject to with respect to its initial
public offering process.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                          38<PAGE>

                                                                   Exhibit 10.23

       PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED ON A REQUEST FOR
                             CONFIDENTIAL TREATMENT

                                SUPPLY AGREEMENT

                                 Deltagen, Inc.

                                Affymetrix, Inc.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

<PAGE>

                                    CONTENTS

<TABLE>
<S>                                                                           <C>
INTRODUCTION...................................................................3
DEFINITIONS....................................................................3
PROBE ARRAY SUPPLY.............................................................9
AFFYMETRIX PROPRIETARY RIGHTS.................................................15
COMPENSATION..................................................................16
INTELLECTUAL PROPERTY.........................................................22
PROJECT COORDINATION..........................................................25
CONFIDENTIALITY...............................................................26
WARRANTY......................................................................27
INDEMNITY.....................................................................28
TERM AND TERMINATION..........................................................30
MISCELLANEOUS.................................................................30

EXHIBIT A: INITIAL FORECAST...................................................20
EXHIBIT B: SYSTEMS PURCHASES..................................................21
EXHIBIT C: FABRICATION VERIFICATION CRITERIA..................................39
EXHIBIT D: RMA................................................................40
</TABLE>

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

<PAGE>

                                SUPPLY AGREEMENT

This Supply Agreement ("Agreement") is effective as of July 12, 2000
("Effective Date") between Affymetrix, Inc. ("Affymetrix") a Delaware
corporation having its principal place of business at 3380 Central Expressway,
Santa Clara, California 95051, and Deltagen, Inc. ("Deltagen") a Delaware
corporation having its principal place of business at 1003 Hamilton Avenue,
Menlo Park, CA 94025.

1        INTRODUCTION

1.1      Affymetrix has research, development, and manufacturing capabilities
         and facilities, and has developed certain rights relevant to DNA probe
         array based technology.

1.2      Deltagen has research and development capabilities, and facilities to
         conduct research and development activities for the generation of
         databases useful in life sciences research.

1.3      Affymetrix and Deltagen desire to enter into an agreement whereby
         Affymetrix will supply Deltagen with DNA probe arrays for use in
         Deltagen's development of database products.

1.4      In consideration of the mutual covenants and promises contained in this
         Agreement, Affymetrix and Deltagen agree as follows:

2        DEFINITIONS

2.1      "Affiliate" shall mean any corporation, company, partnership, joint
         venture and/or firm which is controlled by or controls a Party or is
         under common control with a Party, but only for so long as such
         Affiliate remains an Affiliate of a Party, and only if such Affiliate
         is bound by the terms of this Agreement. For purposes of this Section,
         "control" shall mean, in the case of corporations (or equivalents of
         corporations), direct or indirect ownership of at least *** of the
         stock having the right to vote for directors of such corporation or, in
         the case of partnerships, at least *** of the ownership interest in
         such partnership. Each Party shall be liable to the other Party for
         breach of this Agreement by any of such Party's Affiliates, and any
         such breach shall be deemed a breach by such party.

2.2      "Chip Improvement Inventions" shall mean all those inventions,
         excluding background rights therein, that are conceived and first
         reduced to practice by an employee or contractor of Deltagen or its
         Affiliates at any time during the period beginning on the Effective
         Date and ending *** after termination of this

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -3-
<PAGE>

         Agreement directly resulting from such inventor's use of the Probe
         Arrays supplied hereunder and that specifically relate to probe
         array manufacturing techniques, probe array layouts, and/or probe
         array packaging techniques, and/or to software to extract raw data
         from Probe Arrays *** but not including software or techniques or
         methods for ***, *** and/or *** such data. Deltagen and its
         Affiliates, shall have and retain a perpetual, fully-paid,
         nonexclusive, nontransferable (except pursuant to assignment as
         permitted in Section 12.5), nonsublicensable (except as necessary in
         conjunction with the *** as contemplated in this Agreement),
         world-wide license, and ***, if any, shall have a limited,
         nonexclusive, nontransferable, nonsublicensable internal use only
         right (solely to the extent, and for the sole purpose, and limited
         to the duration of, performing such *** for Deltagen), to each such
         Chip Improvement Invention, for any lawful use, which shall survive
         any termination of this Agreement. It is to be understood that
         neither any other inventions made with respect to the use of Probe
         Arrays nor any inventions made independently of the use of Probe
         Arrays provided hereunder (including, without limitation when made
         through the use of Deltagen's or any third party's proprietary
         technology or knowledge or other intellectual property) are Chip
         Improvement Inventions within the meaning of this Agreement. Chip
         Improvement Inventions shall further not include any other
         inventions that are conceived of or reduced to practice by an
         employee, contractor or customer of a Party or its Affiliates
         including, for example, inventions relating in whole or part to gene
         function, pathways interactions or discoveries resulting therefrom,
         expression data or discoveries resulting therefrom, software
         applications or algorithms used for higher level analysis of
         expression data (beyond that listed in the first sentence of this
         Section 2.2 above), targets identified through the use of the Probe
         Arrays, or correlations between genetic sequences and function (all
         of which are acknowledged and agreed to be the confidential
         information of the Party owning or discovering or developing the
         same, subject otherwise to the protections set forth in Section 8 of
         this Agreement.

2.3      "Committee" shall mean the individuals designated by Deltagen and
         Affymetrix to serve on a coordinating committee as outlined in Section
         7.

2.4      "Confidential Information" shall mean all information and materials,
         patentable or otherwise, of a Party disclosed by or on behalf of such
         Party to the other Party and which derive value to a Party from not
         being generally known, including, but not limited to DNA sequences,
         vectors, cells, substances, formulations, techniques, methodology,
         equipment, data, reports, know- how, trade secrets, pre-clinical and
         clinical trials and the results thereof, sources of supply, patent
         positioning, and business plans, including any negative developments.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -4-
<PAGE>

2.5      "Custom Probe Array" means a custom Probe Array, ***, sold by
         Affymetrix only to Deltagen and/or its Affiliates hereunder.

2.6      "Database" shall mean a collection of Datapoints which is made broadly
         available for license in whole or in part for use to derive additional
         information. A Database shall be considered to have been made "broadly
         available" for purposes of this Agreement if it is made available to
         third parties other than solely as a Service. If a database includes
         both Datapoints and data or information that is not derived directly
         from the use of a Probe Array supplied under this Agreement, then the
         term "Database" as used in this Agreement shall mean only that portion
         thereof which is comprised of Datapoints. In the event that a
         collection of Datapoints is provided on a Service basis and is later
         made broadly available, such collection of Datapoints shall be
         considered a "Service" at the time delivered to a single customer and a
         "Database" from and after the time it is made broadly available.

2.7      "Datapoint" shall mean the data and/or information (such as expression
         levels per Gene) Deltagen or its Affiliates derives directly from use
         of Probe Array(s) supplied under this Agreement which relates to a
         particular Gene represented on such Probe Array(s) and comprising all
         probe pairs on the Probe Array(s) that represent that Gene. ***.

2.8      "Deltagen's Area Of Interest" shall mean the use of Probe Arrays to
         generate gene expression data, for Deltagen's or its Affiliate's
         internal research purposes, Database technology development purposes
         and/or for generating Databases for license, and providing Services, to
         third parties.

2.9      "Demonstration Database" shall mean a Database that (A) omits or has
         disabled substantial functionality and/or features in comparison with
         the corresponding Database standard product and/or contains no more
         than *** Datapoints (as increased proportional to increases after the
         Effective Date in the number of genes in a Probe Array Chipset); (B) is
         used by Deltagen for testing, training, demonstration, promotional,
         marketing or other comparable purposes without charge (excluding
         nominal media charges and Deltagen's normal installation, service
         and/or training fees); and (C) may be used by the recipient for no more
         than *** from receipt. It is understood that Demonstration Databases
         shall not be distributed such that a recipient may assemble multiple
         Demonstration Databases into a Database.

2.10     "Fabrication Verification Criteria" shall mean Affymetrix' then
         current, applicable quality control criteria for Probe Arrays that are
         widely distributed to third parties, which quality control criteria as
         presently constituted have been delivered to Deltagen and which will be
         provided to Deltagen from time to time when a material change is made,
         plus the Specifications, PROVIDED THAT, the Fabrication Verification
         Criteria provided to Deltagen ***. Affymetrix will not

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -5-
<PAGE>

         change the Fabrication Verification Criteria so as to *** to satisfy
         without Deltagen's prior written consent, which shall not be
         unreasonably withheld. Affymetrix' current Fabrication Verification
         Criteria as of the Effective Date is described in Exhibit C and
         includes the following: Detectability = ***, Specificity = ***.

2.11     "Forward Compatibility" shall mean, with respect to the probe pairs
         representing a single gene present on a Probe Array, the preservation
         of the DNA sequences in each and all of such probe pairs between and
         among all other Probe Arrays of the same Probe Array Chipset (including
         subsequent releases and versions of Probe Arrays with different
         specifications, such as an increase in the number or composition of the
         genes comprising the Probe Array Chipset).

2.12     "GATC Compliant" shall mean software and/ or databases meeting the
         standards set forth in accordance with the Genetic Analysis Technology
         Consortium ("GATC") standards group. In the event that the GATC
         standards are no longer maintained, the Parties will negotiate in good
         faith to define substitute specifications for interoperability of their
         respective software and databases.

2.13     "Gene" shall mean a nucleic acid sequence encoding a distinct RNA
         transcript. A Gene may be represented by a partial nucleic acid
         sequence representing an expressed sequence tag (EST). Multiple ESTs
         from the same Gene are considered a single Gene. Polymorphic variants
         of a nucleic acid sequence are considered a single Gene. If a nucleic
         acid sequence encodes multiple distinct RNA transcripts due to
         alternative splicing, each alternative internal splice variant is
         considered a distinct Gene.

2.14     "Lot" shall mean the standard minimum quantities in which Probe Arrays
         are made available to third parties, as set forth in Affymetrix' price
         list and specifications.

2.15     "Net Sales" shall mean the aggregate United States Dollar equivalent of
         gross revenues derived by or payable to Deltagen or its Affiliates for
         the transfer, sale, license, lease or other disposition of
         Databases, or the right to access or use Databases, to third parties
         less a) credits or allowances, if any, actually granted on account
         of price adjustments, recalls, rejections, or return of items
         previously sold, prompt payment discounts, *** actually incurred; b)
         actual trade or quantity discounts actually allowed and taken; c)
         excises, sales taxes, value added taxes, consumption taxes, duties,
         foreign withholding tax actually withheld, or other taxes imposed
         upon and paid with respect to such sales (excluding income or
         franchise taxes of any kind); d) *** insurance, delivery, costs
         actually incurred and e) any *** other payments paid to *** on
         account of *** by, and/or for rights and/or licenses relating to,
         *** or *** or *** and/or their *** as

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -6-
<PAGE>

         contemplated hereby or in their respective *** or other ***. No
         deduction shall be made for any item of cost incurred by Deltagen or
         its Affiliates in preparing, manufacturing, shipping, or selling
         Databases except as permitted pursuant to a), b), c), and d) above
         and the aggregate deductions to Net Sales pursuant to a) above shall
         not exceed ***. Net Sales shall not include (A) any royalties or
         license fees or other payments for (i) licenses under Deltagen's
         patents or other proprietary rights, even if the need for or
         desirability of such license arises out of the use of a Database,
         (ii) any knockout mice, conditional knockout mice, knock-in mice or
         any other animal(s) or any associated sperm, cells, materials or
         tissues, or (iii) licenses or other rights to access or use, or to
         be provided, information or data not directly derived from use of a
         Probe Array, even if such information is also contained within or
         derivable from a Probe Array; (B) any internal use by Deltagen or
         its Affiliates; or (C) any transfer between or among Deltagen and
         any of its Affiliates including if for re-license or resale. If
         Deltagen or an Affiliate licenses or sells to or through a
         distributor (which is not an Affiliate of Deltagen), Net Sales shall
         be the gross revenues (including but not limited to royalties and
         agency fees) received by Deltagen and/ or the applicable Affiliate
         from the license or other transfer of the Database to such
         distributor. In the event that Deltagen or any of its Affiliates
         licenses a Database to third parties for other than monetary value
         in whole or in part, such transfer shall be considered a license
         hereunder for accounting and royalty purposes. In the event cash and
         non-cash consideration or solely non-cash consideration is received
         by Deltagen, Net Sales shall be the cash consideration, if any, plus
         the value of non-cash consideration. Non cash consideration shall be
         determined on a country-by-country basis and shall be the average
         price of comparable arms length licenses solely for cash by Deltagen
         or its Affiliates in such country during the royalty reporting
         period in which such transfer occurs less the amount of cash
         consideration received, if any, or if no such comparable arms length
         licensing occurred in such country during such period, during the
         last period in which such arms length sales occurred. If no arms
         length licenses solely for cash have occurred in a particular
         country, non cash consideration for such transfer shall be the
         average price of comparable arms length licenses solely for cash in
         all countries less the amount of cash consideration received, if
         any. If no comparable arms length licenses solely for cash occurred,
         then the value of non cash consideration shall be valued on an
         equitable basis to be agreed upon by the parties. If a Database is
         sold or licensed as part of a database that includes both Datapoints
         and other information or data and/or as part of a system, package,
         or combination with other product(s), license(s) and/or service(s)
         (collectively, a "Product Bundle"), then the Net Sales attributable
         to the Database for purposes of

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -7-
<PAGE>

         this Agreement shall be calculated by multiplying the Net Sales of the
         Product Bundle during that financial reporting period in question by
         the fraction A/ B where "A" is the average unit price during that
         period of the Database when licensed separately and "B" is the sum of
         all the average unit prices during that period of all of the component
         products and services comprising the Product Bundle when licensed or
         sold separately. If the Database or any other component product or
         service of a Product Bundle is not licensed or sold separately from the
         combination comprising the Product Bundle, then the percentage of the
         Net Sales of the Product Bundle that is attributable to the Database
         shall be an equitable allocation as reasonably determined by the
         Parties (or, if the Parties cannot agree, by arbitration in accordance
         with Section 12.6).

2.16     "Party" shall mean Affymetrix or Deltagen, as the context requires.
         "Parties" shall mean Affymetrix and Deltagen.

2.17     "Physical Defect" shall mean, with respect to a Probe Array, a defect
         in materials or workmanship of such Probe Array, or a defect in such
         Probe array resulting from the manufacture or handling of such Probe
         Array prior to delivery to the common carrier in accordance with
         Section 3.5, such that defect(s) are the cause of impaired
         hybridization of probe pairs, or any other impairment leading to
         materially aberrant Datapoints. Such determination must be made
         pursuant to Affymetrix' then current standard GeneChip expression assay
         protocols and Fabrication Verification Criteria that apply to such
         Probe Arrays.

2.18     "Probe Array" shall mean a solid support having an array of
         polynucleotides with known location and sequence fabricated by
         Affymetrix pursuant to this Agreement for use in expression analysis.

2.19     "Probe Array Chipset" means a set of Probe Arrays representing
         Affymetrix' then-current representation of the genome of a particular
         species or organism.

2.20     "Proprietary Probe Arrays" shall mean Probe Arrays which contain
         substantial proprietary genetic information of a third party for which
         incremental fees are due by Affymetrix to such third party associated
         with the use of such proprietary genetic information.

2.21     "Services" shall mean (i) the "one-off" provision of a custom
         collection of unique (relative to the Database(s) and not just a subset
         thereof) Datapoints for value exclusively to a single third party
         solely for such third party customer's internal use and/or (ii) the
         business of Deltagen using Probe Arrays to generate expression analysis
         information for third party customers on a service bureau basis. The
         term "Service" does not include offering customers the option to
         acquire a subset of the Datapoints that comprise a Database.

2.22     "Software" shall mean the software provided to Deltagen by Affymetrix
         for use with Probe Arrays and Systems.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -8-
<PAGE>

2.23     "Specifications" shall mean Affymetrix' then-current Probe Array
         specifications, current versions (as of the Effective Date) of which
         will be provided to Deltagen within seven (7) days of the execution of
         this Agreement, for the Probe Arrays provided pursuant to this
         Agreement.

2.24     "System(s)" shall mean fluidics station(s), work station(s), probe
         array reader(s), hybridization ovens and any other systems or equipment
         sold to Deltagen pursuant to this Agreement.

2.25     "Term" shall mean the period beginning on the Effective Date and
         ending on a date (a) *** after the Effective Date in the event
         Deltagen elects option (a) to continue under the terms and
         conditions of the "Beginning Period" as set forth in Section 5.1, in
         which case the Term shall be renewable for successive *** periods
         (each, an "Extended Term") upon mutual written agreement by the
         Parties; or (b) *** from the Effective Date in the event Deltagen
         elects option (b) as set forth in Section 5.1, unless extended
         pursuant to Section 5.1 in which case "Initial Term" shall mean the
         initial 3 year portion of the Term and "Extended Term" shall mean
         the potential extension of the Term by *** years pursuant to Section
         5.1.

3        PROBE ARRAY AND SYSTEM SUPPLY

3.1      Only Custom Probe Arrays pursuant to Section 5.12 and those expression
         Probe Arrays listed in Affymetrix' catalog at standard prices will be
         available for purchase pursuant to this Agreement.

3.2      Beginning on the Effective Date, Affymetrix will deliver such
         quantities of the appropriate Probe Arrays meeting the requirements of
         this Agreement, as specified in a properly rendered forecast made
         pursuant to Section 3.4, or, for the first 3 months of the Term,
         according to a forecast previously supplied by Deltagen and attached as
         Exhibit A. All Probe Arrays delivered to Deltagen under this Agreement
         shall have a ***.

3.3      Affymetrix shall maintain a minimum capacity to supply to Deltagen at
         least *** Probe Arrays per month (as used in this Agreement, "month"
         means a calendar month), subject to the next two sentences. In no event
         will Affymetrix be obligated to provide more than *** Probe Arrays in
         any one month (as increased proportional to increases in the number of
         Probe Arrays comprising the Probe Array Chipset(s) purchased by
         Deltagen); provided, however, Affymetrix shall use commercially
         reasonable efforts to fill Deltagen's orders for Probe Arrays in excess
         of said limit. In the event Affymetrix experiences a significant
         decrease in manufacturing yield for a sustained period or other
         manufacturing incapacity (as opposed to intentionally accepting orders
         in excess of Affymetrix's ability to

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -9-
<PAGE>

         timely fill the same), such that Affymetrix is unable to supply
         Deltagen with previously accepted orders of properly forecasted Probe
         Arrays up to the maximum quantity per month obligation set forth in
         Section 3 above ("Qualifying Deltagen Orders"),***.

3.4      Beginning on the Effective Date and on a monthly rolling basis on the
         first business day of each month during the Term of this Agreement,
         Deltagen will provide a reasonable, good faith forecast of Probe Arrays
         to be supplied by Affymetrix during the following *** period or the
         period until the end of the Term if less than *** (such forecasts to be
         supplied by number of Probe Arrays and part number) to Deltagen and its
         Affiliates. The forecast will be provided according to a mechanism and
         on forms consistent with this Agreement and to be agreed upon in good
         faith by the Parties within 30 days after the Effective Date. The first
         and second month of each successive forecast (part number and
         individual quantity) shall constitute a firm order by Deltagen,
         accepted by Affymetrix, for the purchase of Probe Arrays under this
         Agreement. The subsequent months of such forecast will be Deltagen's
         non-binding estimate for capacity planning purposes only, and shall not
         be or constitute a commitment or firm order.

3.4.1    Delivery times for all Probe Arrays ordered hereunder will be on
         date(s), quoted at the time Affymetrix receives a firm order for such
         products, within the month as to which such order relates (subject to
         Sections 3.3 and 3.4 above). If Deltagen requests specific delivery
         date(s) for a firm order, then Affymetrix will use commercially
         reasonable efforts to deliver in accordance with such request.

3.4.2    Unless approved in writing by Deltagen, over-shipment or under-shipment
         of an order in excess of *** shall not be allowed.

3.4.3    If Affymetrix ships an order more than *** or more than ***, then a ***
         shall be applied to such order.

3.4.4    If the number of ordered Probe Arrays for a month increases by more
         than *** from the immediately preceding firm forecast for such month,
         then the number of such Probe Arrays above the *** increase shall be
         supplied in a reasonable time, but shall not be subject to penalty or
         breach on account of late supply thereof for purposes of Section 3.4.3.

3.5      Probe Arrays will be packed in Affymetrix' standard shipping packages
         and shipped to the address specified by Deltagen. Delivery of Probe
         Arrays hereunder will be F. O. B. Affymetrix' facility or the facility
         of its sales representative upon actual delivery to the common carrier
         for shipment to Deltagen. Delivery of Probe Arrays to the common
         carrier will be deemed by the Parties to be a representation by
         Affymetrix that such Probe Arrays have passed Affymetrix' then-current
         standard Probe Array quality control procedures and, meet the
         then-current

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -10-
<PAGE>

         Fabrication Verification Criteria. Affymetrix will ship via a common
         carrier and mode of shipment selected by Deltagen or, if none is
         specified by Deltagen, Affymetrix will select the common carrier and
         mode of shipment. Title and risk of loss or damage for deliveries will
         pass to Deltagen upon delivery at the F. O. B. point. Deltagen will pay
         all shipping costs from the F. O. B. point, duties, and sales taxes.
         Deltagen will advise Affymetrix if insurance is desired on any
         shipments of Probe Arrays, and will reimburse Affymetrix for all such
         insurance charges.

3.6      Subject to provisions herein relating to warranty and support, all
         Probe Arrays will be deemed accepted unless they are returned to
         Affymetrix within 45 days after delivery to Deltagen, with written
         explanation of the basis on which such Probe Arrays have been returned,
         on Affymetrix' standard "Return Materials Authorization" according to
         the procedures provided for in such Return Materials Authorization (a
         current version (as of the Effective Date) of which is set forth in
         Exhibit D). Affymetrix will replace (i) all Probe Arrays that have
         Physical Defects and (ii) the entire affected Lot if more than a
         reasonable number, consistent with Affymetrix' normal quality criteria
         and overall size of the Lot, of the Probe Arrays in that Lot have
         Physical Defects. Replacements of Probe Affrays or Lots pursuant to the
         preceding sentence shall be free of charge to Deltagen and at
         Affymetrix' expense as to both in-bound and out-bound shipping costs.

3.7      Notwithstanding anything to the contrary herein, Affymetrix will
         provide Deltagen, *** in addition to the installation, set up and
         certification activities contemplated by Section 3.13, with (i) up to
         *** qualified instructor-days of training in use of Probe Arrays and
         Systems during the "Beginning Period" (as defined in Section 5.1) and
         up to *** qualified instructor-days of such training per year during
         the remainder of the Term, as requested by Deltagen, in accordance with
         schedules to be mutually and reasonably agreed and (ii) all *** used in
         the course of the standard initial System setup procedure for each
         System installed hereunder. In cases where Deltagen elects to have
         training at Affymetrix' facility, travel and expenses of Deltagen
         personnel will be paid by Deltagen. Additional training will be
         reasonably provided by Affymetrix to Deltagen at the request of
         Deltagen at the then current commercial terms.

3.8      Deltagen may not: 1) transfer the Probe Arrays provided by Affymetrix
         pursuant to this Agreement to third parties other than Deltagen's
         Affiliates and/or research partners who have purchased Affymetrix
         instrumentation systems and have in effect a license from Affymetrix to
         use such systems with Affymetrix probe arrays to perform bona fide
         contract research for the benefit of Deltagen and/or its Affiliates
         (such contract research must be pursuant to a written agreement

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -11-
<PAGE>

         consistent with this Agreement) but only for so long as such license
         remains in effect and such third parties comply with the terms and
         conditions applicable to their use of Affymetrix products ("Research
         Partners"); or 2) transfer the data generated by use of Probe Arrays to
         any third party other than (i) Affiliates, (ii) Research Partners or
         (iii) subscribers to a Database; or 3) use the Probe Arrays provided by
         Affymetrix pursuant to the Agreement to provide services to any third
         party, other than to Affiliates, except as to those Probe Arrays where
         i) the service recipient agrees to limit further distribution of the
         data to other third parties consistent with Affymetrix' normal probe
         array supply terms and conditions as updated from time to time with
         advance written notice to Deltagen (Affymetrix has provided Deltagen
         with a copy of such terms and conditions as in effect as of the
         Effective Date; Deltagen shall use commercially reasonable efforts to
         promptly integrate updates to such terms and conditions not later than
         90 days after Deltagen's receipt thereof, except that unless Deltagen
         elects otherwise, updated terms and conditions shall not apply to any
         binding agreement between Deltagen and the service recipient in
         existence as of the effective date of the update that is consistent
         with the version of such terms and conditions in effect at the time
         such agreement became binding on or the firm commitment of Deltagen),
         and (ii) the applicable fee for Probe Arrays used in Services is paid
         pursuant to Section 5.3; or 4) allow any third party, other than
         Affiliates and Research Partners for use in Deltagen's Area of
         Interest, to use the Probe Arrays supplied by Affymetrix to Deltagen
         under this Agreement; or 5) otherwise use the Probe Arrays delivered
         hereunder outside of Deltagen's Area of Interest; or 6) reuse the Probe
         Arrays; or 7) use Probe Arrays in diagnostic or other similar settings
         requiring FDA or other comparable regulatory agency approval unless
         Deltagen obtains such approval and such Probe Arrays are to be used in
         a clinical trial (and such Probe Arrays are not for microbial or
         pathogenic organisms). Deltagen will allow Affymetrix reasonable,
         periodic (but not more than once per year unless Deltagen has failed to
         comply with the prohibition against reuse) access to the Systems during
         regular business hours and with advance written notice solely to ensure
         compliance with the prohibition against reuse and, in the case of an
         audit conducted by an Affymetrix employee, without access to or
         retention of any expression analysis or other information or data of
         Deltagen or any of its Affiliates and Research Partners or its or their
         customers, licensors or licensees; if Affymetrix utilizes an
         independent auditor, such auditor shall have access to such information
         as reasonably necessary to perform the audit provided that such auditor
         shall not disclose the contents of such information to Affymetrix or
         its Affiliates. Any auditor shall be under reasonable obligations of
         confidentiality.

3.9      All Databases (excluding those provided on a Service basis) transferred
         to a third

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -12-
<PAGE>

         party by Deltagen pursuant to this Agreement will be GATC Compliant ***
         that it is *** to use the GATC standard. Deltagen will bear its
         internal costs of such GATC compliance.

3.10     Deltagen may not sell or license the Databases through a distributor or
         agent except pursuant to written agreement(s) consistent with this
         Agreement.

3.11     Affymetrix will provide to Deltagen all standard System and Probe Array
         information, documentation and manuals and, in any event, sufficient
         genetic information to identify all the Genes on each Probe Array. If
         Affymetrix updates its Probe Arrays to include additional or different
         genetic sequence information, Affymetrix shall provide such information
         to Deltagen promptly, and in any event not later than *** after
         Affymetrix first makes such information *** .

3.12     Upon either Party's request, Deltagen and Affymetrix may reasonably
         cooperate in joint promotional activities of the Databases generated
         hereunder as mutually agreed. Each Party may use the other Party's
         trademarks, logos and tradenames ("Marks")as mutually agreed upon by
         the Parties , provided that the use by a Party of any of the other
         Party's Marks shall be subject to approval by such other Party, which
         approval shall not be unreasonably withheld or delayed. Each Party
         acknowledges the ownership by the other Party of its respective Marks.
         Each Party will maintain a high quality standard in connection with
         products and services promoted in connection with the other Party's
         Marks. If, in either Party's sole discretion, the other Party's use of
         the first Party's Marks does not meet the first Party's trademark usage
         policy as (i) actually complied with by the first Party and (ii) as
         communicated to the second Party in writing, then the first Party may,
         at its option, terminate the second Party's right to use the Marks
         pursuant to this Section 3.11. The parties agree to negotiate in good
         faith joint marketing activities where mutually deemed applicable.

3.13     Deltagen will issue by *** purchase order(s) for the System(s) and
         Software specified on Exhibit B. Promptly upon its receipt of
         Deltagen's purchase order, Affymetrix will *** install and set-up
         (including configuration, testing and certification) the Systems
         ordered hereunder at Deltagen's facility in accordance with Affymetrix'
         standard installation procedures ("Installation"). The Parties will
         cooperate and use all commercially reasonable efforts to complete
         Installation by not later than a date to be mutually agreed upon within
         seven (7) days after execution of this Agreement.

3.14     In the event that Affymetrix makes ***, the Specifications or any other
         material probe array specification(s) such that Deltagen reasonably
         will have to undergo *** or other *** to effectively incorporate
         Datapoints from Probe Arrays incorporating such change into a Database
         or to maintain *** Databases or Datapoints generated before and after
         the change, and Affymetrix provides

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -13-
<PAGE>

         assistance intended to help ameliorate such situation ***.
         Affymetrix shall use its commercially reasonable efforts to ensure
         *** when designing updates or changes to Probe Arrays. If Affymetrix
         is unable to maintain a commercially reasonable level of Forward
         Compatibility in a subsequent version of a Probe Array Chipset
         purchased by Deltagen such that Deltagen's ability (and/or
         associated costs) to generate, populate or maintain its expression
         database products or services are materially and adversely affected,
         then notwithstanding anything herein to the contrary, Affymetrix
         shall *** (subject to the same per *** set forth in Section 5) or,
         alternatively, Deltagen may within 60 days of Affymetrix
         discontinuing of the then previous Probe Array Chipset as a standard
         product offering in its catalogue ***.

4        AFFYMETRIX PROPRIETARY RIGHTS

4.1      Until the end of the Term, Deltagen will not buy probe arrays of
         diverse nucleic acids on solid supports from a third party when such
         third party arrays materially infringes the patent or copyright rights
         (or would materially infringe an allowed but as of then unissued patent
         claim) of Affymetrix or its Affiliates. In order to enforce this
         provision Affymetrix must provide Deltagen a) reasonable and prompt
         written notice of such infringement upon Affymetrix becoming aware of
         such infringement, b) reasonable evidence of such infringement, with
         which counsel for Deltagen reasonably concurs, c) *** for the *** in
         the review contemplated by clause b) preceding, and d) agrees in its
         notice *** to the extent based on a *** or similar claim and to ***
         finally *** for such claim and other *** (including ***) arising out of
         Deltagen's compliance with this section 4.1. In order to avail itself
         of the benefits of (c) and (d) above, Deltagen shall (i) provide the
         notice described in (a) above to Deltagen's counsel within a reasonable
         period of time after receipt of such notice from Affymetrix (reasonably
         sufficient for (b) above to occur) and *** (ie., an agreement or
         commitment not existing as of the date of Deltagen's receipt of
         Affymetrix's notice) obligating Deltagen to buy any probe arrays of
         diverse nucleic acids on solid supports from a third party where ***
         (or would materially infringe an allowed but as of then unissued patent
         claim) of Affymetrix or its Affiliates that are described in such
         notice, and (ii) promptly, upon the occurrence of (b) above, cease all
         negotiations and other interactions with such third party with respect
         to such infringing arrays, provided that if (b) above does occur,
         including if Deltagen subsequent to (a) above has entered into a new
         agreement or other binding commitment after having allowed reasonably
         sufficient time for (b) above to occur, then Deltagen shall terminate

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -14-
<PAGE>

         such agreement or commitment as soon as contractually and legally
         permissible and use its best efforts to abide by all contractual and
         legal requirements applicable to such termination. This Section 4.1,
         PER se, shall not confer on Deltagen or any third party any rights
         under the patent rights of Affymetrix not already licensed as set forth
         in Section 4.2.

4.2      Affymetrix hereby grants Deltagen and its Affiliates a non-exclusive,
         worldwide right and license, subject to Deltagen and its Affiliates
         compliance with the terms and conditions of this Agreement, to (i) use
         the Software (subject further to Deltagen's compliance with Affymetrix'
         standard software license terms and conditions (in written and/or
         "click-through" form) on the workstation(s) provided with the System(s)
         hereunder in accordance with its documentation and manuals to use and
         operate such System(s) (a copy of such license has been provided to
         Deltagen); (ii) use Probe Arrays, data, information and other materials
         provided by Affymetrix pursuant to this Agreement, derive Datapoints
         and generate Databases and Product Bundles therefrom and provide,
         distribute and sublicense Databases and Services, all subject to, and
         in accordance with, the terms and conditions of this Agreement; and
         (iii) otherwise practice and have the quiet enjoyment of the benefits
         and intents of this Agreement, as set forth herein.

5        COMPENSATION

5.1      Deltagen shall pay to Affymetrix a technology access fee of *** on the
         Effective Date which shall cover the period beginning on the Effective
         Date and ending on the whichever of the following occurs first: (i) the
         *** of the Effective Date or (ii) the *** by Deltagen of a Database
         that generates Net Sales (the "Beginning Period"). Beginning on the
         last day of the Beginning Period and continuing throughout the
         remainder of the Term (and any Extended Term), Deltagen shall have a
         ***, exercisable by providing written notice to Affymetrix thirty (30)
         days after the first-to-occur date described in the first sentence, to
         either (a) continue under the terms and conditions applicable during
         the Beginning Period (including without limitation, training
         obligations as set forth in Section 3.7, Probe Array fees as set forth
         in Sections 5.2 and 3, and Database royalties as set forth in Section
         5.5), in which case the "Beginning Period" shall be deemed by the
         Parties to mean, and all such terms and conditions shall exclusively
         apply during, the period beginning on the Effective Date and continuing
         throughout the remainder, if any, of the Term and any Extended Term as
         set forth in this Section; or (b) pay Affymetrix a *** per year
         according to the following payment schedule: *** within 30 days after
         the last day of the Beginning Period and *** at the end of every three
         (3) month period thereafter throughout the remainder of the Term (and

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -15-
<PAGE>

         any Extended Term). In the event Deltagen elects option (b) above,
         Deltagen may extend the Term by *** years by providing written
         notice to Affymetrix no later than ninety (90) days before the end of
         the Initial Term. If so extended for *** years, Affymetrix will
         negotiate in good faith for an additional extension of the Term of the
         Agreement under similar terms for an additional *** years (for a
         potential total Term of up to *** years), provided that Deltagen
         must provide *** before the end of the initial Extended Term of its
         desire to negotiate in good faith for such extension.

5.2      For each expression Probe Array (excluding those Probe Arrays for use
         in internal use or Services) delivered to Deltagen or its Affiliates
         during the Beginning Period that meet the Fabrication Verification
         Criteria, Deltagen will pay a fixed fee per Probe Array of the greater
         of: *** of Affymetrix' then-current regional (relative to where the
         Probe Arrays are to be used by Deltagen) list price for that Probe
         Array, as published in Affymetrix' catalog; or, ***. After the
         Beginning Period and during the remainder of the Term (and any Extended
         Term), for each expression Probe Array (excluding those Probe Arrays
         for use in internal use or Services) delivered to Deltagen or its
         Affiliates that meet the Fabrication Verification Criteria, Deltagen
         will pay a fixed fee per Probe Array of the greater of: *** of
         Affymetrix' then-current regional (relative to where the Probe Arrays
         are to be used by Deltagen) list price for that Probe Array, as
         published in Affymetrix' catalog; or, ***. The foregoing
         notwithstanding, genetic information access fees actually paid by
         Affymetrix to a third party with respect to Proprietary Probe Array(s)
         will not be discounted and will be passed through to Deltagen without
         mark-up as part of the fee payable hereunder with respect to such
         Proprietary Probe Array(s), but only to the extent that the genetic
         information access fees are not reflected in the list price of standard
         equivalently sized Probe Arrays.

5.3      For each Probe Array to be used in Services delivered to Deltagen or
         its Affiliates that meet the Fabrication Verification Criteria,
         Deltagen shall pay *** of Affymetrix' then current local (relative to
         the country in which the Datapoints from such Service is to be used by
         the customer) list as published in its catalog or, if applicable, the
         price for the equivalent probe arrays from Affymetrix then available to
         that particular third party recipient of such Services (if lower). ***
         For each expression Probe Array to be used for Deltagen's internal use
         delivered to Deltagen or its Affiliates during the Term that meet the
         Fabrication Verification Criteria, Deltagen will pay a fixed fee per
         Probe Array of the greater of: *** of Affymetrix' then-current regional
         (relative to where the Probe Arrays are to be used by Deltagen) list
         price for that Probe Array, as published in Affymetrix' catalog; or,
         ***.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -16-
<PAGE>

5.4      Notwithstanding the foregoing or any provision to the contrary in this
         Agreement, Deltagen will be responsible for any and all royalties due
         to third parties for Probe Arrays supplied to Deltagen hereunder and/or
         with respect to the manufacture, sale, reproduction, distribution or
         use of any Database(s) or Datapoint(s). If Deltagen arranges with such
         a third party to pay such a royalty directly to such party, Deltagen
         shall at Affymetrix' request provide reasonably sufficient
         documentation to evidence such direct royalty payments to such third
         party, provided that Deltagen shall not be required to breach any
         confidentiality obligations owed to such third party. In the event ***
         based on a *** use of the Probe Arrays, System(s) or Software provided
         hereunder ***, Deltagen *** provided that if Deltagen *** Affymetrix'
         indemnity obligations, if any, arising from such suit pursuant to
         Section *** shall be limited to Deltagen's continued use of Probe
         Arrays ***.

5.5      At the time and in the manner hereinafter provided, Deltagen shall pay
         to Affymetrix a royalty at the applicable rate according to the table
         below times the Net Sales recognized by Deltagen in accordance with
         GAAP during the applicable royalty reporting period.

<TABLE>
<CAPTION>
        --------------------------------------------------------- ----- ---------------------------------------------
                              TIME PERIOD                                               ROYALTY RATE
        --------------------------------------------------------- ----- ---------------------------------------------
        <S>                                                             <C>
                        During Beginning Period                                             ***
        --------------------------------------------------------- ----- ---------------------------------------------
                         During first year ***                                              ***
        --------------------------------------------------------- ----- ---------------------------------------------
                            Second year ***                                                 ***
        --------------------------------------------------------- ----- ---------------------------------------------
              Third and each subsequent year ***                                            ***
        --------------------------------------------------------- ----- ---------------------------------------------
           After termination of this Agreement (until last to                               ***
        expire Affymetrix patent rights that would otherwise be
                      infringed by such Database)
        --------------------------------------------------------- ----- ---------------------------------------------
</TABLE>

         During the *** of the Beginning Period, and during the period beginning
         on termination of the Agreement and ***, the one-time minimum royalty
         payable by Deltagen per customer/licensee per Database shall be
         calculated according to the following schedule:

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -17-
<PAGE>

<TABLE>
<CAPTION>
         ------------------------------------------------------------------------
                              For Databases Comprised of *
         --------------------------------- ------- ------------------------------ ----------------------------------
         More Than                          But    No More Than                        Minimum Annual Royalty
         --------------------------------- ------- ------------------------------ ----------------------------------
         <S>                               <C>     <C>                            <C>
         *** Datapoints                            The then  applicable  maximum                                ***
                                                   number  of  Datapoints  for a
                                                   Demonstration Database
         --------------------------------- ------- ------------------------------ ----------------------------------
         The  then   applicable   maximum          *** Datapoints                                               ***
         number  of   Datapoints   for  a
         Demonstration Database
         --------------------------------- ------- ------------------------------ ----------------------------------
         *** Datapoints                            *** Datapoints                                               ***
         --------------------------------- ------- ------------------------------ ----------------------------------
         *** Datapoints                            *** Datapoints                                               ***
         --------------------------------- ------- ------------------------------ ----------------------------------
         *** Datapoints                            *** Datapoints                                               ***
         --------------------------------- ------- ------------------------------ ----------------------------------
         *** Datapoints                            *** Datapoints                                               ***
         --------------------------------- ------- ------------------------------ ----------------------------------
         *** Datapoints                            *** Datapoints                                               ***
         --------------------------------- ------- ------------------------------ ----------------------------------
         ***                                                                      Datapoints For Databases comprised
                                                                                  of more than *** Datapoints, the
                                                                                  Parties shall negotiate in good
                                                                                  faith a minimum annual royalty.
         --------------------------------- ------- ------------------------------ ----------------------------------
</TABLE>

         *For purposes of calculating the minimum annual royalty, the size of
         the Database will be measured by the number of Datapoints contractually
         accessible to a customer by way of a contract at inception of the
         applicable contract. It is understood that such licenses are not
         intended to allow license of multiple Demonstration Databases to a
         single customer of the same species that can be combined into a larger
         Database.

         Royalties will be reported and paid quarterly as specified in Section
         5.7. The amount payable per quarter will be calculated according to the
         following formula:

         ***

         Notwithstanding the foregoing, Net Sales otherwise subject to royalties
         accruing pursuant to this Section 5.5 shall be subject to a ***, which
         shall apply to the first *** in Net Sales recognized by Deltagen in
         accordance with GAAP during the term of this Agreement so that,
         notwithstanding the foregoing provisions, ***

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -18-
<PAGE>

         such time as the aggregate ***. However, if this Agreement is
         terminated during the period beginning on the Effective Date and ending
         *** after the Effective Date such *** shall not apply to any Net Sales
         accruing after such termination of the Agreement (even if aggregate Net
         Sales have not exceeded *** as of such termination date).

5.6      Except as to royalty payments, all amounts referred to in this Section
         5 will be invoiced by Affymetrix when due (Affymetrix will invoice for
         Systems and Probe Arrays upon shipment in accordance with Section 3.5).
         Royalty payments will be due as specified in Section 5.7. All payments
         will be made to Affymetrix thirty (30) days from the date of invoicing
         by Affymetrix. Late payments shall bear interest at the rate of ***
         per month. All payments in this Agreement will be made in the form of a
         check or wire transfer to Affymetrix in U. S. Dollars.

5.7      Deltagen shall deliver to Affymetrix, within sixty (60) days after the
         end of each calendar quarter, a written report showing its computation
         of royalty payments due under Section 5.5 of this Agreement, including
         any Net Sales of licenses of Databases by Deltagen or its Affiliates
         during such calendar quarter. All Net Sales shall be segmented in each
         such on a country by country basis, including the rates of exchange
         used to convert such royalties to U. S. Dollars from the currency in
         which the licenses were made. For the purposes of this Agreement, the
         methods and rates of exchange to be used for converting Net Sales in
         foreign currencies into U. S. Dollars for royalty payment purposes
         shall be the same as those used by Deltagen for its financial reporting
         in accordance with GAAP. Simultaneously with the delivery of each such
         report, Deltagen shall tender payment in U. S. Dollars of all royalties
         shown to be due therein. Where royalties are due for licenses of
         Databases in a country where, by reason of currency regulations or
         other legal constraints it is impossible or illegal for Deltagen or its
         Affiliates to transfer royalty payments to Affymetrix, such royalties
         shall be deposited in whatever currency is allowable in a bank in that
         country that is reasonably acceptable to Affymetrix. Any and all income
         or similar taxes imposed or levied on account of the receipt of
         royalties payable under this Agreement which are required to be
         withheld by Deltagen shall be paid or remitted by Deltagen on behalf of
         Affymetrix to the proper taxing authority. Proof of payment or
         remittance shall be secured and sent to Affymetrix as evidence of such
         payment or remittance in such form as required by the tax authorities
         having jurisdiction over Deltagen or its Affiliates. Such withholding
         taxes shall be deducted from the royalty that would otherwise be paid
         by Deltagen or its Affiliates to Affymetrix hereunder.

5.8      Except as provided in Section 5.9, hardware, custom designs, and other
         software, if any, may be acquired/ licensed by Deltagen and its
         Affiliates at Affymetrix'

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -19-
<PAGE>

         regional list prices with discounts and terms no less favorable when
         taken as a whole than granted to other similarly situated un-Affiliated
         licensees or customers of Affymetrix under similar terms and conditions
         (taking into consideration applicable subscription, design and other
         fees payable to Affymetrix by such third parties).

5.9      During the Beginning Period, Deltagen shall purchase the Systems and
         the Software specified on Exhibit B, and may purchase Affymetrix'
         Laboratory Information Management System ("LIMS") and Expression Data
         Management Tool ("EDMT") software at a discount rate of *** from
         Affymetrix' then current regional list prices as published in its
         catalog. After the Beginning Period and during the remainder of the
         Term (and any Extended Term), Deltagen may purchase LIMS and EDMT at a
         discount rate of *** from Affymetrix' then current regional list prices
         as published in its catalog. ***.

5.10     After the Beginning Period, Affymetrix will provide early access to new
         product releases to Deltagen in a manner consistent with its ***
         customers.

5.11     Following Deltagen's request, Affymetrix agrees to consider reasonable
         proposals made by Deltagen in good faith under financial terms
         acceptable to Affymetrix for supply to Deltagen during the Term of
         custom Probe Arrays to be used by Deltagen in generating Databases;
         provided that Affymetrix shall have no obligation hereunder with
         respect to any such proposal and Affymetrix shall be free to reject any
         such proposal for any reason or no reason in Affymetrix' sole absolute
         discretion.

5.12     The parties shall mutually agree upon provisions to be added by written
         amendment to this Agreement concerning Custom Probe Arrays.

6        INTELLECTUAL PROPERTY

6.1      Any invention made during the course of and as part of this Agreement
         shall be owned according to inventorship of the relevant applications.
         Deltagen shall be the owner of all Datapoints and Databases. However,
         Deltagen (and its Affiliates) agree to assign to Affymetrix at
         Affymetrix' cost all Chip Improvement Inventions. Deltagen agrees to
         communicate periodically all technology improvements and developments
         that Deltagen reasonably believes are Chip Improvement Inventions to
         the Committee.

6.2      All Chip Improvement Inventions made available to Affymetrix hereunder
         shall be on an as-is basis. DELTAGEN DISCLAIMS ALL OTHER
         REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT
         LIMITED TO, THE IMPLIED WARRANTIES RELATING TO INTELLECTUAL PROPERTY,
         MERCHANTABILITY, AND

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -20-
<PAGE>

         FITNESS FOR A PARTICULAR PURPOSE. Deltagen makes no warranty that it
         will ever develop any Chip Improvement Invention. Deltagen shall have
         no liability under any theory of strict liability, negligence, whether
         active or passive, or products liability on account of the manufacture,
         use, license, or sale of Chip Improvement Inventions or products or
         Probe Arrays that contain or make use of any Chip Improvement
         Invention.

6.3      Subject to any prior rights of and Deltagen's contractual obligations
         and commitments to third parties (including prior rights and
         contractual obligations and commitments that arise after the Effective
         Date), in the event Deltagen or its Affiliate intends to exclusively
         license a invention to an un-Affiliated third party that is directed to
         a particular *** or its use that was primarily discovered through use
         of Probe Array(s) delivered hereunder, Affymetrix shall have the right
         of first refusal to negotiate with Deltagen or its Affiliate and
         execute an exclusive license to the applicable claims of such invention
         (if any) under mutually agreeable terms and conditions solely in the
         field of manufacture and use of probe arrays and systems (fluidics
         station(s), work station(s), probe array reader(s), hybridization ovens
         and any other systems or equipment) for use therewith manufactured by
         or for Affymetrix or its Affiliate(s). In the event Affymetrix and
         Deltagen are unable to reach agreement with regard to such exclusive
         license within 120 days of Affymetrix receiving notice from Deltagen or
         its Affiliate of such invention claims, Deltagen may then offer such
         license to other un-Affiliated third parties on an exclusive or
         non-exclusive basis provided that Deltagen shall not offer such
         exclusive license to any other un-Affiliated third party on terms and
         conditions more favorable, taken as a whole, to such party than those
         last offered by Affymetrix, taken as a whole, without first offering
         Affymetrix such more favorable terms and a reasonable time period (not
         to exceed 5 business days) for Affymetrix and Deltagen to negotiate
         such license. If Deltagen determines to offer such invention claims for
         license on a non-exclusive basis, Deltagen agrees to negotiate in good
         faith for at least non-exclusive access to Affymetrix under mutually
         agreeable terms and conditions to all Deltagen (and its Affiliates)
         owned inventions that are directed to particular *** or their uses
         that were primarily discovered through use of the Probe Arrays
         delivered hereunder, and such access will only be granted in the field
         of manufacture and use of probe arrays and systems (fluidics
         station(s), work station(s), probe array reader(s), hybridization ovens
         and any other systems or equipment) for use therewith made by or for
         Affymetrix or its Affiliate(s). Such non-exclusive access will be
         negotiated to include royalty and other payments no less favorable,
         taken as a whole, than granted to other similarly situated
         un-Affiliated third party licensees, and need only be provided if
         legally licensable at the time the invention is made. Deltagen

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -21-
<PAGE>

         need not report such inventions until after publication in, for
         example, an issued patent or a patent application (depending on the
         jurisdiction).

6.4      In the event Deltagen or its Affiliate intends to exclusively
         license a invention to an un-Affiliated third party that is directed
         to (a) *** techniques (but only insofar as such *** techniques
         relate to *** or (b) software, techniques or methods for ***,
         Affymetrix shall have the right of first refusal to negotiate with
         Deltagen or its Affiliate and execute an exclusive license to the
         applicable claims of such invention (if any) under mutually
         agreeable terms and conditions solely in the field of manufacture
         and use of probe arrays and systems (fluidics station(s), work
         station(s), probe array reader(s), hybridization ovens and any other
         systems or equipment) for use therewith manufactured by or for
         Affymetrix or its Affiliate(s). In the event Affymetrix and Deltagen
         are unable to reach agreement with regard to such exclusive license
         within 120 days of Affymetrix receiving notice from Deltagen or its
         Affiliate of such invention claims, Deltagen may then offer such
         license to other un-Affiliated third parties on an exclusive or
         non-exclusive basis provided that Deltagen shall not offer such
         exclusive license to any other un-Affiliated third party on terms
         and conditions more favorable, taken as a whole, to such party than
         those last offered by Affymetrix, taken as a whole, without first
         offering Affymetrix such more favorable terms and a reasonable time
         period (not to exceed 5 business days) for Affymetrix and Deltagen
         to negotiate such license. If Deltagen determines to offer such
         invention claims for license on a non-exclusive basis, Deltagen
         agrees to negotiate in good faith for at least non-exclusive access
         to Affymetrix under mutually agreeable terms and conditions to all
         Deltagen (and its Affiliates) owned inventions that are directed to
         particular Genes or their uses that were primarily discovered
         through use of the Probe Arrays delivered hereunder, and such access
         will only be granted in the field of manufacture and use of probe
         arrays and systems (fluidics station(s), work station(s), probe
         array reader(s), hybridization ovens and any other systems or
         equipment) for use therewith made by or for Affymetrix or its
         Affiliate(s). Such non-exclusive access will be negotiated to
         include royalty and other payments no less favorable, taken as a
         whole, than granted to other similarly situated un-Affiliated third
         party licensees, and need only be provided if legally licensable at
         the time the invention is made. Deltagen need not report such
         inventions until after publication in, for example, an issued patent
         or a patent application (depending on the jurisdiction).

6.5      Affymetrix and Deltagen will negotiate in good faith for Deltagen to
         act as a nonexclusive agent for license of Affymetrix' LIMS and EDMT
         software for use with Deltagen's database products, PROVIDED THAT
         notwithstanding anything to the contrary in this Agreement, Deltagen,
         its Affiliates, its Research Partners and its

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -22-
<PAGE>

         customers *** Affymetrix-specified *** or *** in connection with use
         of the *** or *** generated therefrom. To the extent Affymetrix
         specifies that certain *** and *** be used with *** and Deltagen
         elects not to follow such specification, then Affymetrix shall have
         no liability under this Agreement for any damage to such *** or the
         System(s), of any failure in the performance thereof that is caused
         by Deltagen's use of such non-specified ***, and Affymetrix'
         indemnity obligations under Section 10.1 shall not apply to any
         third party claim(s) of infringement caused by Deltagen's use of
         such nom-specified *** or *** (which claims of infringement shall be
         deemed "Non-Covered Claims" for purposes of Section 10.1).
         Furthermore, the foregoing statement of no contractual obligation
         shall not be construed to convey or imply any right or license under
         any intellectual property right of Affymetrix or its Affiliates.

6.6      Deltagen understands that no license is conveyed or implied for use of
         the Systems herein for probe arrays other than those manufactured or
         licensed by Affymetrix.

7        PROJECT COORDINATION

7.1      The parties will form the Committee, which shall be composed of such
         representatives of Affymetrix and Deltagen as each shall respectively
         appoint and be reasonably acceptable to the other Party. Each Party by
         its representative( s) shall cast one vote on the Committee. A quorum
         shall consist of at least one Committee representative from each Party.
         The Committee shall act only with the concurring votes of both Parties.
         A Party's representatives shall serve at the discretion of such Party
         and may be substituted for or replaced at any time by such Party. The
         Committee shall meet at least quarterly during the Term, except at such
         times as the Parties mutually believe there are no significant agenda
         items. The site of such meetings shall alternate between the offices of
         Affymetrix and Deltagen, (or any other site mutually agreed upon by the
         Parties) or be arranged by video conference. The proceedings of all
         meetings of the Committee shall be prepared alternately by the Parties,
         unless otherwise agreed, and sent to both Parties. In the event that
         the Committee is unable to reach a decision by unanimous action with
         respect to any matter and such inability continues for a period of
         forty- five (45) days after the date on which the matter is first
         submitted to the Committee, each Party shall refer the matter to the
         Chief Executive Officers of Affymetrix and Deltagen for resolution.
         Each Party shall set forth in writing a proposed solution to the
         impasse. If an acceptable resolution is not achieved, either party may
         choose to arbitrate the issue( s) in accordance with Section 12.7.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -23-
<PAGE>

         The Parties shall use reasonable efforts to continue performance of
         this Agreement during any such dispute.

7.2      The basic purpose of the Committee shall be to aid in coordinating the
         performance of this Agreement, although each Party shall remain
         responsible for the day to day performance of its respective duties and
         obligations under and pursuant to the terms of this Agreement. The
         charter and authority of the Committee shall be mutually agreed upon by
         the Parties. In no event, however, shall the Committee have the
         authority to amend this Agreement or to waive, or waive the performance
         of, any provision hereof.

8        CONFIDENTIALITY

8.1      For a period of 5 years from disclosure to the other Party, each Party
         shall maintain the Confidential Information of the other Party in
         confidence (including the terms of this Agreement), and shall not
         knowingly disclose, divulge, or otherwise communicate such Confidential
         Information of the other, or use it for any purpose, except as
         permitted or contemplated by this Agreement, and in order to carry out
         the terms and objectives of this Agreement. The Parties will use
         reasonable precautions to prevent and restrain the unauthorized
         disclosure of such Confidential Information of the other Party. The
         provisions of this paragraph and Section 8.2 shall not apply to
         Confidential Information which:

8.1.1    was known or used by the receiving Party or its Affiliates without any
         restriction on disclosure, prior to its date of disclosure to the
         receiving Party, as evidenced by the prior written records of the
         receiving Party or its Affiliates; or

8.1.2    either before or after the date of the disclosure to the receiving
         Party is lawfully disclosed without restriction on disclosure to the
         receiving Party or its Affiliates by an independent, unaffiliated third
         party rightfully in possession of the Confidential Information,
         provided that if such Confidential Information is provided to the
         receiving Party by a third party rightfully in possession of the
         Confidential Information, but with restrictions on disclosure, the
         receiving Party may use such Confidential Information in accordance
         with such restrictions of the third party;

8.1.3    either before or after the date of the disclosure to the receiving
         Party becomes published or generally known to the public through no
         fault or omission of the receiving Party or its Affiliates;

8.1.4    is required to be disclosed by the receiving Party or its Affiliates to
         comply with applicable laws, to comply with a court order, or to comply
         with governmental regulations, provided that the receiving Party
         provides reasonable (prior, if feasible) written notice of such
         disclosure to the other Party and the receiving

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -24-
<PAGE>

         Party cooperates with the other Party, at the other Party's expense and
         upon the other Party's reasonable written request, in taking reasonable
         and lawful actions to avoid and/or minimize the degree of such
         disclosure;

8.1.5    is independently developed by the receiving Party or its Affiliates
         without reference to the Confidential Information.

8.2      Deltagen may not publish in a journal article or other publication any
         benchmark results comparing the use of the Probe Arrays with other
         competitive technologies without the prior written approval of
         Affymetrix. Affymetrix may not publish results of the use of the Probe
         Arrays that include any results derived by Deltagen without the prior
         written approval of Deltagen. Subject to the limitations of the
         foregoing and Section 3 above, Deltagen may publish the results of its
         research and/or use of the Probe Arrays at its sole discretion,
         provided that in no event shall Deltagen publish Affymetrix'
         Confidential Information or Chip Improvement Inventions without
         Affymetrix' consent. In the event that Deltagen chooses to publish such
         results, if Affymetrix scientists have contributed to such work, then
         authorship will be according to scientific input in accordance with
         applicable industry standards for such matters and Affymetrix will
         cooperate in such publications. If a Party decides to make a
         publication that requires the prior approval of the other Party
         pursuant to this Section, then the publishing Party will provide the
         other Party with draft versions of all such publications at least 60
         days prior to submission, for the other Party's approval (and, if
         approval is given, technical review), and will allow for removal of the
         other Party's Confidential Information. For purposes of this Section
         "publication" shall not mean the license of Databases or the provision
         of Services hereunder.

9        WARRANTY

9.1      Both Parties to this Agreement represent and warrant that they have the
         full right and authority to enter into and perform this Agreement.

9.2      Affymetrix warrants that the Probe Arrays delivered hereunder do not
         incorporate the *** of a third party anywhere in the world or, to
         its *** (provided that such obligation to perform *** shall be fully
         satisfied by ***, for purposes of disclosure to the relevant ***
         during ***), *** of a third party in the ***. EXCEPT AS OTHERWISE
         PROVIDED HEREIN, AFFYMETRIX DISCLAIMS ALL OTHER REPRESENTATIONS AND
         WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE
         IMPLIED WARRANTIES RELATING TO MERCHANTABILITY, AND FITNESS FOR A
         PARTICULAR PURPOSE. Affymetrix shall have no liability under any
         theory of strict liability, negligence,

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -25-
<PAGE>

         whether active or passive, or products liability. Affymetrix' entire
         liability shall in no event exceed the compensation hereunder.
         Affymetrix shall have no liability under this Section for any indirect,
         consequential, incidental, or special damages. Deltagen understands
         that the risks of loss herein are reflected in the price of the Probe
         Arrays and access fees and that the terms would have been different if
         there had been a different allocation of risk.

9.3      AFFYMETRIX warrants that (i) all *** provided hereunder shall meet
         the *** and shall be ***, provided that Deltagen's sole and
         exclusive remedy and Affymetrix' sole and exclusive liability for a
         breach of this warranty in this subsection (i) shall be limited to
         those express provisions set forth in Sections 3 and 5 above and
         (ii) for one (1) year from the date of shipping, the System and the
         Software shall be free from defects in design, materials and
         workmanship; shall operate in accordance with Affymetrix' respective
         documentation, manuals and published specifications in all material
         respects; and, in the case of the Software, shall, at the time of
         shipment, constitute the most recent generally available release or
         version thereof. Support services for Software and Systems will be
         provided pursuant to Affymetrix' standard service terms. Affymetrix'
         sole and exclusive liability (and Deltagen's sole and exclusive
         remedy) under the foregoing warranty shall be to repair or replace
         Software and Systems or provide Deltagen a refund, as solely
         determined by Affymetrix. Nonconforming Systems will be serviced at
         Deltagen's facility or, at Affymetrix' option, Affymetrix' facility.
         If service is performed at Affymetrix' facility, Affymetrix will
         bear shipping costs. This warranty does not apply to any defect
         caused by failure to provide a suitable storage, use, or operating
         environment, use of non-recommended reagents, or the use of the
         Probe Arrays, Systems or Software for a purpose or in a manner other
         than that for which they were designed, modifications or repairs
         done by Deltagen, or any other abuse, misuse, or neglect of such
         products. This warranty applies only to Deltagen and its Affiliates,
         and not third parties.

10       INDEMNITY

10.1     Affymetrix will settle or defend any suit or proceeding brought against
         Deltagen and its Affiliates to the extent based on a claim that ***
         delivered hereunder or their *** (e.g., System manuals) *** in the ***.
         Affymetrix will settle or defend any suit or proceeding brought against
         Deltagen to the extent based on a claim that the manufacture, sale or
         license by Affymetrix or its Affiliates of *** delivered hereunder ***
         (i. e. through***) infringes a *** in or by the ***. Affymetrix shall
         have no liability under this paragraph to the extent that the

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -26-
<PAGE>

         alleged infringement arises out of any addition or modification to
         the Probe Arrays or their use by Deltagen not specified by
         Affymetrix in, or not contemplated by, this Agreement or any such
         standard documentation, or Deltagen's combination of the *** with
         other devices not specified or provided by Affymetrix. Patent claims
         that meet all of the following three criteria are referred to herein
         as "Non-Covered Claims:" (i) the claim arises solely out of
         Deltagen's use of the Probe Arrays, System or Software; (ii)
         Affymetrix does not indemnify Deltagen with respect to such claim
         under the first two sentences of this Section 10.1; and (iii) the
         claim is for infringement of a patent issued in or by the ***.
         Deltagen will settle or defend any suit or proceeding arising out of
         Deltagen's specific use of Probe Arrays, which suit or proceeding is
         based on an *** the *** brought against Affymetrix for Non-Covered
         Claims. The indemnifying Party shall pay all damages and costs
         finally awarded against the indemnified Party for such infringement.
         For this paragraph to apply the indemnified Party must inform the
         indemnifying Party within 14 days of notice of any claim or suit
         being made or brought, and give the indemnifying Party the full
         authority, information, and assistance necessary to settle or defend
         such suit or proceeding. The indemnifying Party shall not be bound
         in any manner by any settlement made without its prior written
         consent. Each indemnifying Party's liability hereunder *** shall be
         limited to an amount equal to the total amount paid. In the event
         that the Probe Arrays are held to infringe and their use is enjoined
         as a result of infringement (not limited to those for which it has
         an obligation to indemnify Deltagen), Affymetrix may obtain for
         Deltagen the right to continue using such Probe Arrays, modify them
         to become noninfringing, or grant Deltagen a credit equal to the
         cost of all affected Probe Arrays that are unused, and accept the
         return of such unused Probe Arrays, or, alternatively, a credit
         equal to the amount which Deltagen is legally obliged to pay as a
         royalty to the third party for use of such Probe Arrays. This
         Section 10.1 states the entire liability for infringement of
         intellectual property rights and is in lieu of all other warranties,
         express or implied except as stated in Section 9.

11       TERM AND TERMINATION

11.1     This Agreement shall extend until the end of the Term unless terminated
         earlier by a Party for cause by written notice if the other Party (or
         its Affiliate) materially breaches any material provision of this
         Agreement and fails to substantially cure such breach within 30 days of
         written notice describing the breach and the intent of the notifying
         Party to terminate the Agreement in the event such breach is not

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -27-
<PAGE>

         substantially cured. In addition, in the event Deltagen elects option
         (b) as set forth in Section 5.1, Deltagen may terminate this Agreement
         without cause and without liability to Affymetrix on not less than ***
         prior written notice given at any time within the period beginning ***
         after the end of the *** and ending *** after the end of the ***.

11.2     Upon termination of this Agreement due to expiration of the Term or for
         any reason other than a material, uncured breach by Deltagen of a
         material provision of this Agreement, Deltagen may continue in
         accordance with this Agreement (i) to use the Software, (ii) to use the
         Probe Arrays previously purchased by Deltagen within their specified
         shelf life, all subject to the warranty and return provisions provided
         in this Agreement, and (iii) to use and sublicense the Datapoints and
         Databases.

11.3     Upon termination of this Agreement, the following provisions will
         survive: 2, 3.5, 3.6, 3.8, 3.9, 3.10, 4.2*, 5.2**, 5.3**, 5.4, 5.5***,
         5.6, 5.7, 6, 8, 9, 10, 11.2, 11.3, and 12. (* Except in the case where
         this Agreement is terminated due to a material, uncured breach by
         Deltagen of a material provision of this Agreement.) (** To the extent
         obligations are accrued prior to the termination date.) (*** For the
         avoidance of doubt, Deltagen's obligation to pay royalties for a
         Database shall survive termination of this Agreement and persist until
         the expiration of the last to expire Affymetrix patent rights that
         would otherwise be infringed by such Database.)

12       MISCELLANEOUS

12.1     Deltagen shall keep, and shall cause its Affiliates to keep, for a
         period of at least two (2) years full, accurate, and true books of
         accounts and other records containing all information and data which
         may be necessary to ascertain and verify the fees and royalties payable
         hereunder. During the Term of this Agreement and for a period of two
         (2) years following the time at which the relevant fee or payment is
         due, Affymetrix shall have the right from time to time (not to exceed
         once during a calendar year or once with respect to any given period)
         to have an independent certified public accountant reasonably
         acceptable to Deltagen audit in confidence such books, records, and
         supporting data on reasonable advance written notice and at their
         normal location. Any such audit shall be conducted so as to have the
         minimum impact on the normal conduct of Deltagen's business and
         operations and such auditor shall only disclose to Affymetrix his
         conclusion and summary information showing whether or not Deltagen has
         made correct payment of the fees and royalties payable hereunder, or,
         if not, the extent and nature of any discrepancy. In the event it is
         finally

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -28-
<PAGE>

         determined that there is a discrepancy initially revealed by an audit
         reveals greater than *** in the relevant period, Deltagen will pay any
         reasonable audit fees.

12.2     DELTAGEN UNDERSTANDS THAT THE PROBE ARRAYS DELIVERED HEREUNDER ARE NOT
         FDA APPROVED. DELTAGEN AGREES NOT TO USE THE PROBE ARRAYS DELIVERED
         HEREUNDER IN ANY CLINICAL OR OTHER SETTING REQUIRING FDA REVIEW OR
         APPROVAL EXCEPT THAT DELTAGEN MAY USE THE PROBE ARRAYS IN CLINICAL
         TRIALS WHEN IT OBTAINS ALL REQUIRED FDA OR OTHER REGULATORY APPROVALS
         REQUIRED FOR USE IN SUCH TRIALS. DELTAGEN WILL INDEMNIFY AFFYMETRIX FOR
         ANY CLAIMS MADE BY A PATIENT ARISING FROM THE USE OF THE PROBE ARRAYS.
         THE PROBE ARRAYS AND SYSTEMS ARE NOT LICENSED EXCEPT AS SPECIFICALLY
         RECITED HEREIN UNDER ANY INTELLECTUAL PROPERTY RIGHTS OF AFFYMETRIX.

12.3     SUBJECT TO SECTION 9 AND 10, NEITHER PARTY SHALL ANY LIABILITY FOR
         PUNITIVE, EXEMPLARY, CONSEQUENTIAL, INCIDENTAL, OR SPECIAL DAMAGES.

12.4     Neither Party nor any of its Affiliates shall originate any news
         relating to this Agreement without the prior written approval of the
         other Party, which approval shall not be unreasonably withheld, or
         except as otherwise required by law.

12.5     Either Party may assign any rights or obligations of this Agreement
         to (i) an Affiliate, (ii) any third party who acquires all or
         substantially all of the relevant assets of the assigning Party by
         merger or sale of assets or otherwise or (iii) with the written
         consent of the other Party (not to be unreasonably withheld), any
         other third party. Notwithstanding the foregoing and only at
         Affymetrix' option, to be exercised by providing notice in writing
         to Deltagen within *** business days of having received written
         notice of the pendency of such transaction, if Deltagen is acquired
         by or otherwise makes an assignment hereof to a company or an
         Affiliate of a company that, at the time of assignment, either (i)
         has *** (defined as a *** whose primary source of gross revenue is
         derived from sale of *** and such gross revenue is not less than
         ***) in *** (including, without limitation, if this provision were
         applicable as of the date of this Agreement, *** or (ii) is a party
         or an Affiliate of *** or its Affiliate with respect to
         allegation(s) of ***, then, provided that Affymetrix (A) refunds to
         the assignee or Deltagen (as Deltagen elects) the pro-rated portion
         of the payment under Section 5.1 for the remainder of the year in
         which the assignment occurs; (B) agrees in writing that the assignee
         is not obligated to make payment under this Agreement other than
         unpaid amounts (if any) due with respect to period(s) ending on or
         before the date of assignment and, subject to the *** royalties

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -29-
<PAGE>

         accruing on Net Sales of the ***; and (C) *** (including cost of
         capital), all of *** as of the date of assignment (if Deltagen so
         elects), then such assignee's rights hereunder shall be limited to
         *** that either existed prior to such assignment by Deltagen or, if
         Deltagen elects not to have *** pursuant to clause (C) preceding,
         are *** after such assignment from use of *** in Deltagen's *** as
         of the date of assignment, and such assignee shall not, without
         Affymetrix prior written consent which Affymetrix may withhold for
         any reason or no reason in Affymetrix' absolute sole discretion, be
         entitled hereunder to *** nor otherwise create ***.

12.6     This Agreement shall be construed according to the laws of California
         without regard to conflict of law provisions.

12.7     In the event of any controversy or claim relating to, arising out of or
         in any way connected to any provision of this Agreement ("Dispute"),
         the Parties shall seek to settle their differences amicably between
         themselves. Any unresolved Dispute shall be finally resolved by final
         and binding arbitration. Whenever a Party shall decide to institute
         arbitration proceedings, it shall give written notice to that effect to
         the other Party. The Party giving such notice shall refrain from
         instituting the arbitration proceedings for a period of ten (10) days
         following such notice to allow the Parties to attempt to resolve the
         Dispute between themselves. If the Parties are still unable to resolve
         the dispute, the Party giving notice may institute the arbitration
         proceeding under the rules of the American Arbitration Association
         ("AAA Rules"). Arbitration shall be held in Palo Alto, California. The
         arbitration shall be conducted before a single arbitrator mutually
         chosen by the Parties, but if the parties have not agreed upon a single
         arbitrator within fifteen (15) days after notice of the institution of
         the arbitration proceeding, then the arbitration will be conducted by a
         panel of three arbitrators. In such case, each Party shall within
         thirty (30) days after notice of the institution of the arbitration
         proceedings appoint one arbitrator. The third and presiding arbitrator
         shall then be appointed by the AAA in accordance with AAA Rules. All
         arbitrator(s) eligible to conduct the arbitration must undertake in
         writing as a condition of service to render their opinion( s) promptly
         after the final arbitration hearing. No arbitrator (nor the panel of
         arbitrators) shall have the power to award punitive damages or any
         award of multiple damages under this Agreement and such awards are
         expressly prohibited. Decisions of the arbitrator(s) shall be final and
         binding on the Parties. Judgment on the award of the arbitrator(s) may
         be entered in any court having jurisdiction thereof. Except to the
         extent entry of judgment and any subsequent enforcement may require
         disclosure, all matters relating to the arbitration, including the
         award, shall be held in confidence by the Parties.

12.8     The waiver by either Party of a breach or a default of any provision of
         this

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -30-
<PAGE>

         Agreement by the other Party shall not be construed as a waiver of any
         succeeding breach of the same or any other provision, nor shall any
         delay or omission on the part of either Party to exercise or avail
         itself of any right power or privilege that it has or may have
         hereunder operate as a waiver of any right, power or privilege by such
         Party.

12.9     This Agreement and the documents referred to herein are the full
         understanding of the Parties with respect to the subject matter hereof
         and supersede all prior understandings and writings relating to the
         subject matter herein. No waiver alteration or modification of any of
         the provisions herein shall be binding unless in writing and signed by
         the Parties by their respective authorized representatives. In the
         event of a conflict or inconsistency between the provisions of this
         Agreement and the provisions of any license or other documentation
         provided by Affymetrix with the Systems, Software, Probe Arrays,
         reagents or any other Affymetrix product, then the provisions of this
         Agreement shall govern.

12.10    The headings in this Agreement are for convenience only and shall not
         be considered in construing this Agreement.

12.11    In the event that any provision of this Agreement is held by a court of
         competent jurisdiction to be unenforceable because it is invalid or in
         conflict with any law of any relevant jurisdiction, the validity of the
         remaining provisions shall not be affected, and the rights and
         obligations of the Parties shall be construed and enforced as if the
         Agreement did not contain the particular provision(s) held to be
         unenforceable.

12.12    This Agreement shall be binding on and inure to the benefit of the
         Parties and their successors and permitted assigns.

12.13    None of the provisions of this Agreement shall be for the benefit of or
         enforceable by any third party.

12.14    Any notice required under this Agreement shall be made by overnight
         mail or courier to the addresses below.

         If to Deltagen:

                  Deltagen, Inc.
                  1003 Hamilton Avenue
                  Menlo Park, CA 94025
                  Attn: President (with a copy to General Counsel)
                  Facsimile Number: (650) 752-0202

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -31-
<PAGE>

         If to Affymetrix:
                  Affymetrix, Inc.
                  3380 Central Expressway
                  Santa Clara, California 95051
                  Attn: General Counsel
                  Facsimile Number: (408) 481- 4709

12.15    "Force Majeure" shall mean an Act of God, flood, fire, explosion,
         earthquake, strike, lockout, casualty or accident, war, civil
         commotion, act of public enemies, blockage or embargo, or any
         injunction, law, order proclamation, regulation, ordinance, demand or
         requirement of any government or any subdivision, authority
         representative thereof, or the inability to procure or use materials,
         labor, equipment, transportation or energy sufficient to meet
         manufacturing needs without the necessity of allocation, or any other
         cause whatsoever, whether similar or dissimilar to those enumerated
         above, which are beyond the reasonable control of such Party, which the
         party affected has used its reasonable best efforts to avoid, and which
         prevent, restrict or interfere with the performance by a Party of its
         obligations hereunder. The Party affected by Force Majeure shall give
         notice to the other Party promptly in writing and whereupon shall be
         excused from those obligations hereunder, to the extent of such
         prevention, restriction or interference, provided that the affected
         Party shall use its commercially reasonable efforts to overcome, avoid
         or remove such cause(s) of non-performance and shall continue
         performance whenever such cause(s) is removed with all possible speed.
         Nothing herein shall be deemed to require any Party to settle on terms
         unsatisfactory to such Party with regard to any strike, lockout or
         other labor difficulty, any investigation or proceeding by any public
         authority or any litigation by any third party.

12.16    This Agreement may be executed in any number of counterparts, each of
         which shall be deemed an original but all of which together shall
         constitute one and the same instrument.

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -32-
<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their properly and duly authorized officers or representatives as set forth
below.

Affymetrix, Inc.

By:  /s/ Susan E. Siegel
   ---------------------------------

Name: Susan E. Siegel
     -------------------------------

Title: President
      ------------------------------

Date: 7/12/00
     -------------------------------

Deltagen, Inc.

By: /s/ William Matthews
   ---------------------------------

Name: William Matthews
     -------------------------------

Title: Chief Executive Officer
      ------------------------------

Date: July 12, 2000
     -------------------------------

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -33-
<PAGE>

                                    EXHIBIT A

                          INITIAL PROBE ARRAY FORECAST

TBD

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -34-
<PAGE>

                                    EXHIBIT B

                          SOFTWARE AND HARDWARE ORDERS

<TABLE>
<CAPTION>
ITEM NUMBER                DESCRIPTION                                 QUANTITY
--------------------------------------------------------------------------------
<S>                        <C>
                                       ***
</TABLE>

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -35-
<PAGE>

                                    EXHIBIT C

                        FABRICATION VERIFICATION CRITERIA

I.       GENE EXPRESSION ARRAY FABRICATION VERIFICATION

         -  ***

              -  ***

              -  ***

         -  ***

              -  ***

              -  ***

II.      CHIP DESIGN QUALITY CHECK

         -  ***

              -  ***

              -  ***

              -  ***

III.     QC TESTING PROCEDURE

         -  ***

              -  ***

              -  ***

         -  ***

              -  ***

              -  ***

IV.      GE ARRAY QC TESTING PROCEDURE

         -  ***

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -36-
<PAGE>

              -  ***

              -  ***

              -  ***

         -  DOP AD027

              -  Assay

                   -  ***

                   -  ***

              -  Analysis

                   -  ***

                   -  ***

V.       GE ARRAY QC TESTING CRITERIA

         1. ***

              -  ***

         2. ***

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -37-
<PAGE>

                                    EXHIBIT D

                                       RMA

[***] Confidential Treatment Requested. The confidential portions have been
filed separately with the Securities & Exchange Commission.

                                      -38-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]